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Abstract 
    Formulation issues, including stability, solubility and bioavailability, have been 
identified as key concerns in anti-cancer drug development. The challenges in 
pharmaceutical formulation often arise from the different physicochemical attributes of a 
molecule and the need to deliver the compound to a desired site. The major problems of 
small molecule drug formulation development are poor water solubility and off target 
toxicity. In chapter 2 of this dissertation, a prostate specific membrane antigen (PSMA) 
targeted micelle was made to deliver a PI3K inhibitor, TGX-221, for prostate cancer 
treatment. The in vitro cell culture based study indicated that the targeted micelle 
significantly improved cellular uptake by PSMA positive cells. The in vivo animal efficacy 
study showed that the targeted micelle significantly reduced tumor size and progression 
in a xenograft model. Ridaforolimus, a non-prodrug rapamycin analog, has entered 
clinical trials for cancer treatment. Formulations of ridaforolimus being evaluated in the 
clinical trials include intravenous infusion and oral administration. The intravenous bolus 
formulation of this drug is very limited due to poor water solubility (ca. 200 µg/mL). In 
chapter 3, we showed that a new formulation of ridaforolimus using DSPE-PEG2000 
micelle as a carrier greatly improved the drug solubility, increasing it 40 times. In 
addition, the pharmacokinetic properties examined in rats showed that this formulation 
significantly increased drug retention in the plasma. In chapter 4, a hyaluronic acid-
rapamycin conjugate was synthesized and characterized. The disposition and efficacy 
of the drug conjugate were studied and demonstrated that the hyaluronic acid drug 
conjugate could be used for treating localized CD44 positive cancer. In chapter 5, a 
doxorubicin prodrug was developed for enhancing oral bioavailability. Doxorubicin was 
chemically conjugated with quercetin, a flavonoid, via a glycine linker. Quercetin is a P-
iv 
 
glycoprotein inhibitor; thus, it prevents doxorubicin efflux by this mechanism. The oral 
bioavailability of DOX was significantly improved in rats through this prodrug strategy. In 
the last chapter, an HPLC method was developed for the separation of active 
compounds from degraded alternol, which could be used for alternol manufacturing and 
stability studies. 
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Chapter 1  
Formulation Development of Anti-Cancer Drugs 
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Cancer is a major public health problem in the United States and other countries (1-
4). One in four deaths in the United States is due to cancer (5), with lung, stomach, 
liver, colon and breast cancers contributing the most (GLOBOCAN, 2008). In 2012, a 
total of 1,660,290 new cancer cases and 580, 350 cancer deaths were projected in the 
United States (Cancer Statistics, 2013). Compared to 1991, the risk of cancer death in 
America has decreased by 20 % (6). Two out of three people diagnosed with cancer 
today in the US survive at least 5 years (American Cancer Society, 2013).  However, 
the deaths from cancer worldwide are estimated to continue rising with a projected 14.1 
million deaths in 2030. About 70 % of all cancer deaths in 2008 occurred in low- and 
middle-income countries (WHO, 2013).  
Chemotherapy is an integral component of treatment for most cancers, and it is often 
combined with surgery, radiation and hormone therapy (7, 8). Even though cancer is no 
longer considered an incurable disease, the treatments for many cancers often fail due 
to the adverse side-effects of treatment or inconsistent outcomes from the drugs (9, 10).  
Improved formulation development has emerged as a potential avenue for improving 
the efficacy and safety of chemotherapy (11, 12). The development of new vehicles and 
drug formulations could enhance drug delivery to the target tissue while minimizing side 
effects and increasing patient compliance (13). There are at least four known 
physiological and biological barriers for anti-neoplastic drug delivery. The first barrier is 
the heterogeneous angiogenesis in tumor tissues (14). Normal cells cannot live if they 
lack adequate nutrition and oxygen. The dysregulation of angiogenesis in tumor tissue 
induces heterogeneous blood flow in different regions within the tumor. At the early 
stages of tumor growth, there are some regions of high blood flow to the tumor for 
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nutrition transport. However, at advanced stages, increasing areas of the tumor have 
very little or no blood flow resulting in poor penetration of the anticancer drug (15). The 
second barrier is the tremendous spatial and temporal heterogeneity permeability of 
tumor vessels (16). The connections between the tumor cells and the adjacent 
perivascular/endothelial cells are tightly associated; thus, the vascular permeability of 
the drug is dramatically reduced (17). The third barrier of anti-cancer drug delivery is the 
interstitial compartment (18). Larger molecule tends to penetrate through the interstitium 
slowly, and the movement of the drug in this compartment is driven by diffusion and 
convection. Furthermore, the remarkably high interstitial tumor pressure results in rapid 
removal of drugs from tumor extracellular space. The fourth barrier is the cell membrane 
and the cytoplasm. Many macromolecules and charged compounds are poorly 
absorbed due to poor partitioning properties. For oral drug delivery, the high acidity in 
the stomach and the enzymes in digestive tract contribute an additional barrier to 
systemic absorption (19). Most protein and peptide drugs are degraded in the 
gastrointestinal compartment before they enter the bloodstream.   
Nanoparticles used as drug delivery systems exhibit unique physical, optical, 
electronic and useful biological properties that can be very helpful for cancer treatment 
(20). During the last two decades, scores of nanoparticle delivery systems have been 
developed for chemotherapy, such as lipid-based nanoparticles (21, 22), polymer-based 
nanoparticles (23, 24), metal-based nanoparticles (25, 26) and biological nanoparticles 
(27, 28). Nanotechnology has been intensively studied as a novel vector for tumor 
directed drug delivery.  
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Nanoparticle formulations have the potential to improve the therapeutic efficacy of 
anticancer agents, change the pharmacokinetic properties of the compound by their 
enhanced permeability and retention (EPR) effect (29), alter protein binding and 
increase plasma retention. The tumor tissue has leaky vasculature and lack of lymphatic 
drainage (30). Nanoparticles smaller than 200 nm (for extravasculation) (31) and larger 
than 10 nm (to avoid renal clearance) (32) tend to accumulate in the tumor site and 
reduce non-specific drug distribution to normal organs. The biggest challenge of passive 
tumor targeting is the inability to achieve a sufficiently high level of drug concentration at 
the target spot resulting in low therapeutic efficacy and eliciting undesirable systemic 
adverse effects. In comparison, active tumor targeting can be achieved by conjugating 
target molecules to the surface of particles. The targeting moieties can recognize and 
bind to specific ligands that are expressed uniquely on the cancer cell’s surface (33). 
The combination of active targeting with nanoparticles is particularly useful for the 
treatment of primary tumors that have not yet metastasized.  Molecules can be used for 
the development of targeted nanoparticles including monoclonal antibodies (34), 
aptamers (35), oligopeptides (36) and small molecules, such as folate (37). 
 Nanoparticle technology has several potential benefits over traditional small molecule 
formulation. Firstly, the aqueous solubility of the drug can be significantly improved (38, 
39). For poorly water soluble compounds, the dissolution velocity is the rate limiting step 
for drug absorption, which is one of the leading causes of low oral bioavailability. Based 
on the Noyes-Whitney equation, which describes the dissolution rate of the drug in a 
diffusion controlled process, the dissolution velocity of the drug can be improved by 
increasing the surface area. Secondly, the particles can deliver the drug molecules 
specifically to the target site in a sustained and controlled manner (40). The 
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nanoparticle formulation can prolong drug circulation time, enhance the therapeutic 
index and decrease drug toxicity. Therefore, a reduction in frequency and dosing is 
possible during treatment. 
Polymeric micelles are spontaneously formed from amphiphilic polymers in aqueous 
media. The hydrodynamic diameters of the micelles are in the range of 20 – 80 nm. The 
driving force is the disruption of water molecule by the hydrophobic blocks. A small 
diffusion coefficient, as low as 10-16 to 10-18 cm2/sec, is required for sustained and 
controlled release of the drug from micelle particles (41). Micelle formulations have 
been intensively studied for hydrophobic drug delivery. One example of a micelle 
formulation of doxorubicin that entered a phase II clinical trial is SP1049C. The micelle 
matrix of SP1049C consists of Pluronic® L61 and F127 (1:8 w/w). After injection, the t1/2 
of SP1049C was 50 h, which is longer than the doxorubicin alone (t1/2 = 30 h) (42). 
Poly(ethylene glycol) (PEG) is a bio-compatible and bio-degradable synthetic polymer 
approved by the FDA for internal use. PEG is widely used in the shell forming block of 
the micelle. The high hydration and rapid motion properties of PEG prevent particle 
interaction with proteins and mononuclear phagocytic system clearance in the blood 
stream. Ishihara et al. studied the biodistribution of a PEGylated polymeric nanoparticle 
in mice (43). They demonstrated that compared to the conventional nanoparticle, the 
PEGylated particle significantly prolonged body circulation time and enhanced drug 
accumulation at the target site. In addition, the functionalized PEG end could be used 
for conjugating a targeting moiety onto the micelle’s surface. Active targeting of the 
micelles can be achieved by this approach. Farokhzad et al. formulated a prostate 
specific membrane antigen targeted PEGylated nanoparticle for the delivery of 
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docetaxel (44). After a single injection of the formulation, complete tumor reduction was 
observed in 5 out of 7 mice, and 100 % animal survival was achieved.  
The toxicity and side effects of an anti-cancer agent can be reduced as well through a 
micelle formulation. This is due to the minimization of non-specific tissue binding of the 
drug. For example, in a preclinical study, PEG-b-poly(L-lactic acid) micelles increased 
the maximum tolerable dose of paclitaxel from 20 to 100 mg/kg after intraperitoneal 
administration in mice (45). 
The core of a polymeric micelle is made of a hydrophobic block of the amphiphilic 
copolymer. This is the primary site of residence for the hydrophobic drug. The 
hydrophobic block governs the capacity of a micelle’s solubilization. Therefore, a key 
optimization factor in micelle formulation is the compatibility of the molecule with the 
hydrophobic core (46). The compatibility is related to the structural and polar similarities 
between the drug and hydrophobic block of the amphiphilic copolymer. The goal is to 
minimize the Flory-Huggins interaction parameter between the poorly water soluble 
drug and the core-forming hydrophobic block. The minimization of Flory-Huggins 
parameter presents the ideal situation for drug solubilization. The polymer used as drug 
delivery carrier should be biocompatible and biodegradable (47). The commonly used 
polymers for micelle cores are poly(esters), such as poly(lactic acid), poly(lactic-co-
glycolic acid) and poly(caprolactone); phospholipid. 
Over the past decade, polymer-drug conjugates with a variety of structures and 
chemical properties have been investigated in the clinic (48), and there are more than 
10 polymer-anticancer drug conjugates currently under clinical trials. The ongoing 
clinical trials of polymer drug conjugates includes HMPA copolymer-doxorubicin (PK1), 
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PEG-poly(aspartic acid)-doxorubicin (NK 911), poly L-glutamic acid-paclitaxel (Xyotax), 
HMPA copolymer-platinate (AP5346), PEG-camptothecin and PEG-SN38 (49). 
Pharmacokinetics and bio-distribution of a drug could be changed through chemical 
conjugation with a highly functionalized polymer molecule (50). However, the toxicities 
differed in the polymer drug conjugate model, not only are drugs attached to the 
polymeric carriers, but a targeting moiety is also introduced to the same polymeric 
carrier to achieve specific targeting (51). The advantages of polymer drug conjugates 
over their parent drugs includes fewer side effects, improved efficacy and toxicity of the 
therapeutic agents, increased patient compliance and ease of drug administration. For 
instance, the clinical safety dose of N-(2-hydroxypropyl) methacrylamide (HPMA) 
copolymer-doxorubicin conjugate (FCE28068) is approximately 4 - 5 folds higher than 
doxorubicin hydrochloride solution (52). By administration of HPMA-doxorubicin 
conjugate containing galactosamine (FCE28068), which presents extra-hepatic 
galactose receptors, doxorubicin concentration in hepatoma tissue was 12-50 folds 
higher than the free drug and the maximum tolerate dose was significantly lower than 
FCE28068(53).  
Examples of therapeutic nanoparticle formulations of anti-cancer drugs in clinics and 
under clinical evaluations are summarized in Table 1. 
 
 
 
 
8 
 
Table 1: Nanoparticle formulations of anticancer drugs in clinic or under clinical 
evaluations.   
Name Description Phase 
Doxil®/Caelyx® Liposome formulation of doxorubicin 
FDA 
approved 
PK1  
(FCE 28068) 
Doxorubicin-HPMA polymer conjugate  Phase II 
PK2 
(FCE28069) 
Doxorubicin-HPMA polymer conjugate with 
galactosamine  
Phase II 
Abraxane® Albumin-bound paclitaxel 
FDA 
approved 
NK105 
Micelle formulation of paclitaxel (mPEG-
polyaspartate) 
Phase III 
Genexol-PM® Micelle formulation of paclitaxel (mPEG-PDLLA) 
FDA 
approved 
Xyotax® Paclitaxel-poly L-glutamic acid conjugate Phase IV 
NC-6004 Polymeric micelle of cisplatin (PEG-poly amino acid) Phase II 
Lupron Depot® GnRH  loaded PLGA nanoparticle 
FDA 
approved 
CALAA-01 
Targeted nanoparticle with the combination of 
RONDELTM and a patented siRNA 
Phase I 
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A prodrug is a medication that is an inactive bioreversible derivative form of a drug 
molecule (54). Prodrugs undergo enzymatic and/or chemical transformation to release 
the active parent drug in the body. Depending on where the body converts the prodrug 
back to its active form determines their classification.  Prodrugs can be classified into 
two types. The type I prodrugs are bioactivated inside the cells, such as anti-viral 
nucleoside analogs. Type I prodrugs that have been tested in clinical trials include: 
acyclovir, 5-fluorouracil, carbamazepine, captopril, heroin, psilocybin, etc.  Type II 
prodrugs are activated outside the cells, especially in digestive fluids or in the body’s 
circulation system (55). Commercially available type II prodrugs include: 
lisdexamfetamine, loperamide oxide, oxyphenisatin, bambuterol, acetylsalicylate and 
fosphenytoin. Using a prodrug strategy, site-specific drug delivery for cancer treatment 
can be achieved. 
The strategy of using enzyme activated prodrugs has been widely used in cancer 
treatment (56). Prodrugs can be selectively activated in tumor tissues by exogenous 
enzymes followed by systemic administration. These directed enzyme prodrug 
therapies include gene-directed enzyme prodrug therapy (GDEPT) (57), virus-directed 
enzyme prodrug therapy (VDEPT) (58), antibody-directed enzyme prodrug therapy 
(ADEPT) (59), polymer-directed enzyme prodrug therapy (PDEPT) and clostridia-
directed enzyme prodrug therapy (CDEPT).  
In this dissertation, different formulations of several potent anticancer agents were 
developed. Pharmacokinetics, tissue distribution and efficacy of the formulated 
anticancer drugs showed significant improvement in treated animals. These 
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investigations could have a significant impact on cancer treatment and address a critical 
need in the field of cancer research and/or patient care. 
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Chapter 2 
 Localized Prostate Cancer Treatment Using PI3K Inhibitor Loaded PSMA-
Targeted Nanoparticles 
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2.1 Introduction 
     The phosphatidylinositol 3-kinase (PI3K)/ phosphatase and tensin homolog 
(PTEN)/Akt pathway is highly involved in different types of cancer (1). PI3Ks are a 
family of enzymes that phosphorylate PI(4,5)P2 (PIP2) to PI(3,4,5)P3 (PIP3). PIP3 is a 
lipid-signaling second messenger that further activates its downstream effectors, such 
as Akt, PDK1 and Rac1/cdc42 (2). The activation of Akt stimulates cell growth, 
proliferation and survival (3). PTEN is a phosphatase that dephosphorylates PIP3 back 
to PIP2 (4). The missing function of PTEN results in accumulation of PIP3, which 
mimics the over activation of PI3K and triggers cell growth. PTEN deficiency is found in 
many types of cancers, such as prostate cancer (LNCaP), brain cancer (U87MG) and 
breast cancer (BT549) (5-7). 
    There are three classes of PI3K isoforms. The most commonly studied class I PI3Ks 
are further divided into classes IA and IB. Only class IA enzymes are clearly implicated 
in human cancers. Class IA PI3K enzymes consist of a p110 catalytic subunit and a 
regulatory subunit. There are three highly homologous p110 catalytic isoforms: 
p110alpha, p110beta and p110delta (8, 9). p110beta is a promising target in cancer 
therapy (10, 11) and PTEN-deficient tumor cells mainly depend on p110beta for 
signaling and growth, not p110alpha (9). 
    The synthetic small molecule TGX-221 (Fig. 1) is a potent, selective and cell 
membrane permeable inhibitor of PI3K p110 beta catalytic subunit, which is critical for 
cell growth, proliferation and tumorigenesis of PTEN-deficient tumor cells including 
prostate cancers (12, 13). Therefore, PI3K p110 beta inhibitors have a great promise as 
novel chemotherapeutic agents to treat PTEN deficient cancer cells (13). However, 
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TGX-221 is poorly soluble and requires organic solvents, such as DMSO or propylene 
glycol, for intravenous injection, which may cause cardiac toxicity, unconsciousness, 
arrhythmia and cardiac arrest (14).  
The therapeutic index of anticancer drugs is often very narrow, and the cytotoxic dose 
of the drug in the desired tissues can be maintained over an extended period of time 
with minimal side effects by targeted delivery and controlled drug release (15, 16). Both 
passive and ligand-targeted nanoparticles have been developed for targeted delivery of 
cancer therapies (17, 18). Passively targeted nanoparticles can accumulate to a greater 
extent in tumors compared to healthy tissues due to the enhanced permeability and 
retention (EPR) effect. The high accumulation of nanoparticles in the tumor tissues is a 
consequence of the poorly aligned endothelial cells allowing nanoparticles to escape 
from the blood circulatory system and to pool in the tumor where there is a lack of 
effective lymphatic drainage (19, 20). Micelles are attractive nanoparticles for the 
delivery of hydrophobic drugs, since they form spontaneously in water after co-mixing 
the drug with an amphiphilic polymer. Both polyethylene glycol (PEG) and 
polycaprolactone (PCL) are FDA approved biocompatible and biodegradable materials. 
Micelles formed by PEG-PCL block copolymers have been used as an effective drug 
delivery system for lipophilic molecules (21-23). Upon pooling in the tumor, micelles will 
slowly release the drug and then dissolve into non-toxic degradation products (24). 
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Fig. 1: Structure of (a) TGX-221; (b) BL05; (c) BL05-HA and (d) BL05-PA. 
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Nanoparticles actively targeted via ligand binding can target cancer cells that over 
express specific receptors or proteins (16). The ligands, monoclonal antibodies or 
aptamers, can recognize and bind to complementary molecules expressed on the tumor 
cells.  We hypothesized that the delivery of a TGX-221 analogue to prostate cancer 
cells may be improved if the drug is encapsulated in targeted-nanoparticles. The 
cancer-targeted nanoparticles should be effective in suppressing tumor growth and 
metastasis with reduced or lack of side effects associated with drug toxicities to normal 
tissues. 
      Aptamers are single- or double-stranded oligonucleotides that are modified to have 
high binding affinity and specificity to their targets (25), and they have emerged as a 
novel class of active targeting moieties for therapeutic and diagnostic applications in 
cancer treatment. Prostate specific membrane antigen (PSMA) expression is confined 
primarily to prostate tissues (26, 27). The expression of PSMA in other tissues, such as 
the brain and small intestines, is approximately 1,000-fold less than that in the prostate 
(28). Prostate specific membrane aptamer A10 (PSMAa10) has nM affinity to the 
membrane expressing PSMA, and it can be used to achieve specific targeting of the 
nanoparticles to prostate cancer cells (29).  
Due to the high biocompatibility of PEG-PCL block copolymers and the specific 
expression of PSMA on prostate cancer cells, the combination of PEG-PCL and 
PSMAa10 in a nanoparticle delivery system is promising for the targeted therapy of 
prostate cancer.  
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2.2 Materials and Methods 
2.2.1 Materials 
    Azide poly(ethylene glycol) (MW: 5,800) was purchased from Polymer Source 
Inc. (Quebec, Canada). Propargyl-dPEG®1-NHS ester was purchased from 
Quanta BioDesign Ltd. (Powell, Ohio). PSMAa10 { 5’-[NH2-(CH2)6-PEG18-GGG 
AGG ACG AUG GGG AUC AGC CAU GUU UAC GUC ACU CCU UGU CAA 
UCC UCA UCG GC inverted T]-3’, 2’F pyrimidines } was custom synthesized by 
Integrated DNA Technologies (Coralville, IA). ε-caprolactone, IR-820, pyrene, 1-
amino-3-butyne and 1-M HCl in diethyl-ether were purchased from Sigma-Aldrich 
Co. (St. Louis, MO). Resazurin blue, silica gel and the organic solvents were 
purchased from Fisher Scientific (Pittsburgh, PA). 
2.2.2 TGX-221 and prodrug synthesis 
All chemicals were used as received unless stated otherwise. NMR spectra 
were taken on a 400-MHz Bruker with the solvent peak as an internal reference. 
Mass spectra were run in the Electrospray Ionization Mass Spectrometry (ESI-
MS) mode or Atmospheric Pressure Chemical Ionization Mass Spectrometry 
(APCI-MS) mode. Reactions that required an inert atmosphere were carried out 
under dry argon with flame-dried glassware. Tetrahydrofuran (THF) was freshly 
distilled over sodium-benzophenone. Dichloromethane (DCM), N, N-
dimethylformaldehyde (DMF) and triethylamine (TEA) were freshly distilled over 
CaH2. The synthetic scheme of TGX-221 and its analog BL05 are shown in 
Scheme 1. 
Synthesis of compound 1. Malonyl dichloride (3.2 mL, 32.0 mmol) was added 
dropwise to a solution of 2-amino-3-bromo-5-methylpyridine (5 g, 26.7 mmol) in 
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dry DCM (50 mL) cooled to 0 oC. The mixture was stirred at ambient temperature 
(ca. 22 oC) for 48 h. The yellow precipitate was collected by filtration, washed 
with DCM (3 x 50mL), and dried under reduced pressure. The desired compound 
was obtained with a yield of 86 % (4.88 g), and identity was confirmed by 1H-
NMR. The crude compound was used in the next step without any further 
purification. The filtrate was concentrated by rotary evaporator. The resulting 
residue was suspended in 100 mL of H2O, and the suspension was stirred at 
ambient temperature for 1 h. The suspension was filtered and the filtrate was 
neutralized with solid Na2CO3 to recover the unreacted 2-amino-3-bromo-5-
methylpyridine (0.84 g). 
Synthesis of compound 2. Compound 1 (4.88 g, 19.13 mmol) was 
suspended in dry DCM (100 mL), and TEA (5.40 mL, 38.3 mmol) was added 
dropwise at 0 oC followed by methanesulfonyl chloride (MsCl) (2.90 mL, 26.8 
mmol). The mixture was stirred at ambient temperature for 1 h. Morpholine (5.0 
mL, 57.4 mmol) was added and the mixture was refluxed for 24 h. The solvent 
then was removed under reduced pressure, and the mixture was diluted with 
H2O to afford a pale yellow precipitate. The solid was collected by filtration, 
washed with 2 x 50 mL of H2O, and dried under reduced pressure. The residue 
was purified through a silica flash column using EtOAc: hexanes 3:1 as the 
eluting solvent. The desired compound was obtained as a yellow solid with a 
yield of 42 % (2.61 g). 
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Scheme 1: Synthesis of TGX-221 (Compound 5) and BL05 (Compound 8). 
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Synthesis of compound 3. Compound 2 (2.53 g, 7.80 mmol) in dry DMF (50 
mL) was mixed with N, N-diisopropylethylamine (4.0 mL), butyl vinyl ether (5.0 
mL) and dichloro 1,1’-bis(diphenylphosphino)ferrocene palladium (II) (0.25 g, 
0.20 mmol) at ambient temperature under argon for ca. 30 min until a 
homogeneous solution was formed. The solution then was heated to 120 oC and 
stirred for another 16 h. After the solution cooled, it was poured into 200 mL of 1-
M HCl at 0 oC. The mixture then was stirred at ambient temperature overnight 
and extracted with DCM (2 x 100 mL). The combined organic phases were 
washed with water and dried over Na2SO4. Removal of the solvent under 
reduced pressure followed by purification of the resulting residue through a silica 
flash column using EtOAc: hexanes 3:1 as the eluting solvent led to the desired 
compound with a yield of 60 % (1.35 g). 
Synthesis of compound 4. Compound 3 (1.35 g, 4.69 mmol) in DCM and 
methanol (5 : 1, 84 mL) was combined with NaBH4 ( 0.70 g, 18.5 mmol) in 5 
portions at 0 oC . After 10 min, the cooling bath was removed and the mixture 
was stirred at ambient temperature for 3 h. Then the mixture was cooled to 0 oC 
and 20 mL of H2O was added slowly. The mixture was extracted with DCM (2 x 
50 mL). The combined organic phases were washed with water (2 x 50 mL) and 
brine (30 mL) and then dried over Na2SO4. Removal of the solvent under 
reduced pressure followed by purification of the resulting residue through a silica 
flash column using EtOAc: hexanes 3:1 as the eluting solvent led to the desired 
compound with a yield of 86 % (1.17 g). 
Synthesis of compound 7. A solution of compound 4 (1.17 g, 4.05 mmol) in 
10 mL of dry DCM was cooled to 0 oC, and MsCl (1.70 mL, 24.3 mmol) was 
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added dropwise followed by dry TEA (1.35 mL). After 10 min, the cooling bath 
was removed, and the reaction proceeded at ambient temperature for ca. 4 h 
until TLC showed that the starting material was consumed completely. The 
resulting mixture was washed with water (50 mL), 2-M aqueous NaOH (50 mL) 
and brine (50 mL), and then dried over Na2SO4. Removal of the solvent under 
reduced pressure followed by purification of the resulting residue through a silica 
flash column using EtOAc: hexanes 1:2 as the eluting solvent led to the desired 
compound as a pale yellow solid with a yield of 93 % (1.39 g). 
Synthesis of TGX-221 (compound 5). A solution of compound 4 (0.70 g, 1.91 
mmol) in 10 mL of dry DCM was cooled to 0 oC, and aniline (0.5 mL, 16.3 mmol) 
was added dropwise followed by dry TEA (1 mL). The mixture was refluxed for 4 
h and then stirred at ambient temperature overnight. The mixture was washed 
with water (2 x 50 mL) and brine (50 mL), and then dried over Na2SO4. Removal 
of the solvent under reduced pressure followed by purification of the resulting 
residue through a silica flash column using EtOAc: hexanes 3:1 as the eluting 
solvent led to the desired compound as a pale yellow solid with a yield of 80 % 
(0.56 g).   
Synthesis of 2-(Phenylamino)ethanol (compound 6). Following the 
procedure of Bhanu et al (30), a mixture of aniline (4.66 g, 50 mmol) and 2-
bromoethanol (4.34 g, 33 mmol) was heated at 90 oC under an argon 
atmosphere for 4 h. The resulting solid was dissolved in ethyl acetate (100 mL), 
washed with 2-M aqueous NaOH (3 x 20 mL) followed by brine (50 mL), and then 
dried over Na2SO4. Removal of the solvent under reduced pressure followed by 
purification of the resulting residue through a silica flash column using EtOAc: 
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hexanes 1:2 as the eluting solvent led to the desired compound with a yield of 
89 % (4.03 g). 
Synthesis of compound 8 (BL05). A solution of compound 5 (0.47 g, 1.28 
mmol) in 10 mL of dry DCM was cooled to 0 oC, and a solution of 2-
(phenylamino)ethanol (0.70 g, 5.12 mmol) in 5 mL of dry DCM was added  
dropwise followed by dry TEA (1 mL). After 10 min, the mixture was refluxed for 
ca. 15 h until TLC showed that the starting material was consumed completely. 
The resulting mixture was washed with 2-M aqueous HCl, water, saturated 
NaHCO3 aqueous solution and brine, and then dried over Na2SO4. Removal of 
the solvent under reduced pressure followed by purification of the resulting 
residue through a silica flash column using EtOAc: hexanes 5:1 as eluting 
solvent led to the desired compound with a yield of 69 % (0.36 g). 
Synthesis of BL05-palmitate derivative (BL05-PA). BL05 (compound 8) 
(0.10 g, 0.24 mmol) and palmatic anhydride (0.24 g, 0.48 mmol) were suspended 
in 10 mL of dry DCM, and 0.20 mL of dry pyridine was added dropwise. The 
mixture was stirred overnight at ambient temperature until TLC showed that the 
starting material was consumed completely. The resulting mixture was washed 
with 2-M aqueous HCl (30 mL), water, saturated NaHCO3 aqueous solution and 
brine. Removal of the solvent under reduced pressure followed by purification of 
the resulting residue through a silica flash column using EtOAc: hexanes 3:1 as 
the eluting solvent led to the desired compound with a yield of 95 % (0.15 g). 
Synthesis of BL05-hexanoate derivative (BL05-HA). A solution of BL05 
(compound 8) (0.18 mg, 0.45 mmol) in 5 mL of dry DCM was cooled to 0 oC, and 
hexanoyl chloride (0.26 mL, 1.80 mmol) was added followed by dry pyridine (0.38 
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mL). After 10 min, the cooling bath was removed, and the reaction proceeded at 
ambient temperature overnight until TLC showed that the starting material was 
consumed completely. The resulting mixture was washed with 2-M aqueous HCl, 
water, saturated NaHCO3 aqueous solution and brine. The organic phase was 
dried over Na2SO4. Removal of the solvent under reduced pressure followed by 
purification of the resulting residue through a silica flash column using EtOAc: 
hexanes 2:1 as the eluting solvent led to the desired compound as a pale yellow 
solid with a yield of 91 % (0.266 g). 
2.2.3 Synthesis of Azide Poly(ethylene glycol)-block-Poly(ε-caprolactone) 
Copolymers ( N3-PEG-PCL) 
    All glassware were flamed dried under vacuum and were handled under a dry 
argon stream. The N3-PEG-PCL copolymer was prepared by acid catalyzed ring-
opening polymerization reaction of ε-caprolactone in the presence of N3-PEG-OH 
as an initiator. The typical process is described as follows. N3-PEG-OH was 
azeotropically dried using anhydrous toluene under reduced pressure. ε-
caprolactone was dried over CaH2 overnight and then distilled under vacuum. N3-
PEG-OH (0.375 g, 0.0647 mmol) was dissolved in 8 mL of dry DCM, followed by 
the addition of 0.75 mL of ε-caprolactone (100 eq). The polymerization was 
initiated by the addition of 1-M HCl in diethyl ether (0.8 mL, 3 eq) at 25 ℃. After 
24 h, the mixture was poured into diethyl ether to precipitate the copolymer. 
Then, the N3-PEG-PCL copolymer was further purified by precipitation in cold 
acetone. The residual solvent was removed under reduced pressure.  
2.2.4 Characterization of the polymeric material 
    The N3-PEG-PCL was dissolved in CDCl3 for 
1H-NMR spectroscopy. Gel 
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permeation chromatography (GPC) was used to determine the polymer 
molecular weight distribution. GPC analysis was performed on a Shodex GPC 
LF-804 column thermostated at 40℃ with DMF and 10-mM LiCl as the mobile 
phase at a flow rate of 0.8 mL/min. Peaks were detected using a refractive index 
detector (RID-10A, Shimadzu). Narrow molecular weight distribution polyethylene 
glycols (Scientific Polymer Products Inc., Ontario, NY) were used as standards 
for GPC analysis. 
2.2.5 Lipid nanoparticle preparation 
2.2.5.1 Solid lipid nanoparticle (SLN)  
Three formulation methods were used to make SLN: thin film, hot 
homogenization and solvent precipitation. Particle sizes were measured by 
dynamic light scattering. Drug release studies were performed in PBS at 37 °C. 
2.2.5.1.1 Thin film 
In a round bottom flask, 50 mg solid lipid, Compritol® 888 ATO or 
Dynasan® 114, and 25 % (w/w) surfactant, lecithin, were dissolved in 5 mL 
chloroform. The mixture was stirred at ambient temperature until all the 
components were dissolved. Then, the organic solvent was evaporated using 
a rotary evaporator under reduced pressure. A thin layer of a uniform film was 
formed on the bottom of the flask. The thin film was then dried overnight 
under the vacuum. The dried thin film was re-hydrated with 5 mL co-
surfactant solution, 2.5 % (w/w) S-40 polyoxyl stearate in ddH2O. To reduce 
the particle size, the nanoparticle solution was sonicated on ice for 2 min 
using a sonic dismembrator (Fisher Scientific, Pittsburgh, PA). 
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2.2.5.1.2 Hot homogenization 
    In a glass vial, 0.1 g Dynasan® 114, a low melting point solid lipid, and 0.05 
mL Tween 80, the surfactant, were heated and melted. The melted lipid 
mixture was poured into 10 mL hot ddH2O with 0.5 % Tween 80 under 
sonication.   
2.2.5.1.3 Solvent precipitation 
    In a glass vial, 0.05 g solid lipid, Dynasan ® 114, and 0.05 g surfactant, 
lecithin, were mixed and fully dissolved in 1 mL chloroform. The oil phase was 
drop-wise added to the co-surfactant solution, 5 % sodium taurocholate in 
ddH2O. The organic solvent was removed by dialysis method. 
2.2.5.2 Nanostructured lipid carrier  
    In a round bottom flask, 50 mg Apifil® or Compritol® 888 ATO (solid lipid), 50 
mg Stepan® 108 or alpha- tocopherol (oil), 10 mg Phospholipon® 90H 
(surfactant) and 2.5 mg PEG2000-DSPE were dissolved in 2 mL ethanol. The 
mixture was stirred at ambient temperature until all the compounds were fully 
dissolved. The oil phase was drop-wise added to 10 mL co-surfactant solution, 
5 % sodium taurocholate in ddH2O. 
2.2.6 Poly(lactide-co-gylcolid) (PLGA) nanoparticle preparation 
     PLGA polymer with different inherent viscosities (0.23 dl/g, 0.69 dl/g and 1.05 
dl/g) were used to make PLGA nanoparticles. PLGA (35 mg) was dissolved in 3 
mL acetone. The organic phase was added to 15 mL surfactant solution, 0.1 % 
Pluronic® F-127 or PVA, using a syringe pump. The nanoparticle solution was 
purified by dialysis against 0.2 % mannitol for 2 days using 100-kDa cutoff 
dialysis tubing.   
31 
 
2.2.7 PEG-PCL micelle preparation 
The N3-PEG-PCL (15 mg, 1.3 mmol) was dissolved in 0.5 mL of 
dimethylacetamide (DMAc) and the organic solution was added dropwise to 2 mL 
of ddH2O with mechanical stirring. The organic solvent was removed by overnight 
dialysis against phosphate buffered saline (PBS) using 10-kDa molecular weight 
cutoff (MWCO) dialysis tubing (Spectrum Laboratories, Rancho Dominguez, CA). 
Drug-loaded micelles were prepared by mixing the drugs with the copolymer in 
DMAc before adding ddH2O. 
The aptamer, PSAMa10, was functionalized by addition of an alkyne group 
using the following procedure. PSMAa10 (0.2 μmol, 3.7 mg) was dissolved in 500 
μl of 0.1-M carbonate buffer (pH 9.0). The alkyne-NHS ester (2.3 mg) was 
dissolved in 60 μl of DMSO, and 6 μl of the alkyne-modified NHS ester solution 
was added to the carbonate buffer containing the aptamer. After mixing for 4 h at 
ambient temperature, the alkyne modified PSMAa10 was purified using a 
centrifugal filtration device (Amicon® Ultra Centrifugal Filter 10K, Millipore Corp.). 
The near infrared dye, IR-820, was modified to include an alkyne by 
conjugation of 1-amino-3-butyne. Briefly, 150 mg of IR-820 (0.177 mmol) was 
dissolved in 10 mL of DMF. Then, 61 mg of 1-amino-3-butyne (5 eq) and 123 μL 
of TEA (5 eq) were added. The solution was stirred at 40 ℃ for 8 h. The final 
product was purified by silica flash chromatography using EtOAc: methanol 1:2 
as the elution solvent. 
Both alkyne modified PSMAa10 and IR-820 were conjugated to the micelle’s 
surface by azide alkyne Huisgen cycloaddition (i.e. click reaction). Briefly, 50 μg 
of alkyne modified PSMAa10 and 100 μg of alkyne modified IR-820 were added 
32 
 
to N3-PEG-PCL micelles (2.5 mg/mL) prepared in ddH2O. Copper sulfate (0.6 
μmol/mL) and sodium ascorbate (3.0 μmol/mL) were used as a catalyst. The 
reaction mixture was gently stirred at ambient temperature overnight. The 
modified micelles were purified by dialysis against PBS using 10,000 MWCO 
dialysis tubing (SnakeSkin® Pleated Dialysis Tubing, Thermo Scientific) for 24 h. 
To determine the extent of the reaction, the supernatant was separated from the 
micelle solution using a Microcon YM-100 centrifugal concentrator (0.5-mL 
capacity, NMWL 100, 000, Millipore Corp.) at 11,000×g for 15 min. The filtrate 
was analyzed by high-performance liquid chromatography (HPLC) (LC-2010CHT, 
Shimadzu). 
2.2.8 Micelle characterization 
The critical micelle concentration (CMC) of N3-PEG-PCL micelles was 
determined by measuring the excitation ratio of pyrene using a fluorophotometer 
(RF-5301 PC, Shimadzu). For example, solutions of N3-PEG-PCL micelles were 
prepared by serial dilution and then incubated with 0.6-μM pyrene for 1 h at 65 ℃ 
and then 18 h at ambient temperature in the dark. The fluorescent emission of 
pyrene was measured at 390 nm. The fluorescent excitement ratio of pyrene at 
339 and 334 nm changes in response to the probe’s microenvironment polarity. A 
sharp increase in the 339/334 excitation ratio indicates the CMC as the pyrene 
preferentially partitions into the hydrophobic core of N3-PEG-PCL micelles. 
The formation of micelles was determined by GPC (Shodex OHpak SB-803 
HQ, Showa Denko America, Inc.) using a Shimadzu 2010CHT system. GPC was 
performed using ddH2O as the mobile phase with a flow rate of 0.8 mL/min, and 
the GPC column was thermostated at 40 ℃. Elution peaks were detected using 
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an evaporative light scattering detector (ELSD-LTII, Shimadzu). The size and 
polydispersity of micelles were measured with a ZetaPALS (Brookhaven 
Instruments Corp.) using the Gaussian distribution.  
The drug loading efficiency (DL %) and encapsulation efficiency (EE %) of 
BL05-HA in PEG-PCL micelles were calculated according to the following 
equations: 
DL % =
weight of the drug in micelle
weight of the  polymer and drug
 × 100 % 
EE % =  
weight of the drug in micelle
weight of the feeding drug
 × 100 % 
GPC micelle fraction was collected and dried by speed-vap. The dried micelle 
fraction was weighed to determined weight of the polymer and drug. Then, the 
dried micelle was redissolved in MeOH and drug weight in micelle was evaluated 
by HPLC analysis.  
2.2.9 Cytotoxicity assay 
    The prostate cancer cell lines DU145 and LNCaP were maintained in RPMI-
1640 medium, and PC3 cells were maintained in F-12K medium (ATCC, 
Manassas, VA). LNCaP is a PSMA positive cell line, whereas DU145 and PC3 
are PSMA negative. Both were supplemented with 10 % fetal bovine serum 
(Hyclone Laboratory Inc., Logan, Utah). Cells were plated in 96-well flat-
bottomed plates at a concentration of 5,000 cells per well in 90 μL of growth 
medium. After 12 h, TGX-221, BL05, or BL05-HA loaded micelles in PBS were 
added at concentrations of 0, 0.1, 1, 5, 10, 50 or 100 µM. PBS and 10 μL of 
trichloroacetic acid (TCA) were added to negative and positive control wells, 
respectively. After 72 h, 10 μL of 55-μM resazurin blue was added to each well 
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and incubated at 37 °C for 4 h. After incubation, the resorufin product was 
measured with a fluorophotometer (SpectraMax Gemini; Molecular Devices, CA) 
using an excitation wavelength of 560 nm and an emission wavelength of 590 
nm. The IC50 was determined as the midpoint between positive and negative 
control groups for each plate using GraphPad Prism 5 software (GraphPad 
Software Inc., San Diego, CA).  
2.2.10 Western blot assay 
    After serum starvation for 16 h, LNCaP cells were treated with 2-µM TGX-221 
or BL05 and 100-ng/mL EGF for 30 min. Then, cells were pelleted and lysed with 
cell lysis buffer containing protease inhibitors. Protein concentrations were 
determined by BCA assays, and equal amounts of protein extract were separated 
on a 10 % SDS-polyacrylamide gel, transferred to a nitrocellulose membrane and 
immunoblotted with anti-pAkt (Ser-473) and Akt (Cell Signaling Technology, Inc., 
Danvers, MA) followed HRP-conjugated secondary antibodies (Santa Cruz 
Biotech, Inc., Santa Cruz, CA). The specific bands were detected using a 
chemiluminescence luminal reagent (Santa Cruz Biotech, Inc., Santa Cruz, CA). 
2.2.11 In vitro drug release study 
    The in vitro release of the drug from N3-PEG-PCL micelles into PBS (pH 7.4) 
was monitored by a dialysis method (31). Dialysis was carried out at 37 °C under 
sink condition using 10-kDa MWCO dialysis tubing (SnakeSkin®, Thermo 
Scientific Inc., Rockford, IL). The initial volume of drug-loaded micelles in the 
dialysis tubing was 5 mL and the sink solution was 4 L. The PBS was changed 
several times per day to maintain sink conditions. After pre-determined time 
intervals, samples were withdrawn from the dialysis tubing and analyzed by 
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HPLC with a reversed phase column (TSK-GEL ® ODS-100Z, Tosoh Bioscience) 
at 50 ℃ with UV detection at 280 nm. The chromatography conditions were a 
mobile phase A of 100 % ddH2O and B of 100 % methanol at a flow rate of 1 
mL/min. The gradient program was i) a linear gradient from 50 % to 90 % solvent 
B over 5 min; ii) 3.5 min with 90 % solvent B; iii) 6.5 min with 100% solvent B; 
and iv) 10 min with 50% solvent B. Retention times: TGX-221 6.86 min; BL05 
6.93 min; BL05-HA 10.14 min and BL05-PA 17.04 min. 
2.2.12 Uptake of PSMA-targeted micelles by prostate cancer cells 
Fluorescence microscopy was used to examine cellular uptake of IR-820-
labeled PSMA-targeted micelles. PSMA negative PC3 cells and PSMA positive 
LNCaP cells were seeded at a density of 1 × 106 cells in an 8.6-cm2 chamber 
slide system (Thermo Scientific). After cells had attached to the microscope 
slide’s surface, the PC3 and LNCaP cells were incubated with the PSMA-
targeted (2.5 % weight compared with polymer concentration) or non-targeted 
micelles for 6 h at 37 ⁰C. Unbound micelles were removed by washing 3 times 
with PBS. Fluorescence images were acquired using a Cy5 filter set on a Nikon 
Eclipse 80i microscope equipped for epifluorescence and an Orca ER camera 
(Hamamatsu Inc., Bridgewater, NJ).   
The cellular uptake and accumulation of PSMA targeted micelles (2.5 % weight 
compared with polymer concentration) was quantified in LNCaP and PC3 cells.  
Cells were seeded in 96-well flat-bottom plates at a concentration of 5,000 cells 
per well in 90 μL of growth medium. After the cells attached to the surface, 10 μL 
of targeted or non-targeted IR-820-modified micelles were added at different 
concentrations. After 6 h of incubation, the growth medium was removed and 
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each well was washed with PBS. The plate fluorescence was measured using a 
fluorophotometer at an excitation wavelength of 675 nm and an emission 
wavelength of 750 nm. 
2.2.13 Pharmacokinetic evaluation 
    Male Balb/c mice were maintained in a temperature-controlled room with a 12 
h light/dark cycle for at least one week prior to the study.  The animal protocol 
was approved by the Institutional Animal Care and Use Committee (IACUC) at 
the University of Kansas Medical Center. Animals were administered BL05-HA 
loaded PSMA-targeted micelles or BL05-HA prepared in propylene glycol at a 
dose of 30 mg/kg via tail vein injection (100 µl). Blood samples were withdrawn 
after 5 min, 1, 2, 4, 6, 12 and 24 h from the saphenous vein. A 20-µL blood 
sample was added to 50 µL of Alsever’s solution, which is an anticoagulant. After 
gently mixing, the blood sample was centrifuged at 3,000 rpm for 10 min. Plasma 
was prepared by solid phase extraction (SPE) prior to the HPLC analysis. Briefly, 
plasma sample diluted with 2% NH4OH (1:3) was applied to the SPE column 
(Bond Elut-C18, Agilent Technologies, Lake Forest, CA) that was pretreated with 
100% MeOH and equilibrated with 100 % ddH2O. Sample was washed with 5% 
MeOH in ddH2O and eluted twice with 150 μL 100 % MeOH. 
2.2.14 Efficacy study in xenograft models 
Four prostate cancer cell lines, androgen-responsive, LAPC-4 and LNCaP, and 
androgen non-responsive, C4-2 and 22RV1, were used to generate the 
subcutaneous xenografts (n = 8). Once xenografts were palpable (30 mm3 in 
size), animals were divided randomly into three groups to receive treatment twice 
a week. The animals were treated with the solvent PPG (as the control), naked 
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TGX-221 analog BL05 in PPG (BL05) and PSMAa10 aptamer-conjugated 
nanocarrier with BL05 (APT-Nano-BL05). The total volume of drug solution was 
200 µl for tail vain injection. Tumor growth was monitored twice a week and 
animals were sacrificed once the xenograft tumor in control groups reached the 
limit of tumor size set by our IACUC. One hour before sacrifice, animals were 
injected with BrdU solution to label the newly synthesized DNA for evaluating 
tumor cell proliferation. After tumor dissection, half of the tumor specimens were 
stored in -80 °C for further analysis and another half of the specimens were 
subjected for paraffin processing. 
2.2.15 Statistical analysis 
    GraphPad Prism 5 software was used for statistical analysis. A t-test was used 
to test for differences between two data sets, while a one-way ANOVA and Tukey 
post test was used to analyze the differences when more than two data sets 
were compared. In all comparisons, statistical significance was set at p ≤ 0.05. 
2.3 Results 
2.3.1 Drug synthesis 
We successfully synthesized TGX-221, BL05 and the fatty acid prodrugs. The 
synthesis of TGX-221 was accomplished with 2-amino-3-bromo-5-methylpyridine 
and malonyl dichloride as the starting materials through 6 steps with an overall 
yield of 14 % and BL05 with an overall yield of 12 %. The structure of each 
compound was determined by 1H-NMR, 13C-NMR or together with high resolution 
APCI-MS or ESI-MS. 
Compound 1: 1H-NMR (DMSO-d6, 400 MHz): δ = 8.74 (s, 1H), 8.29 (s, 1H), 
5.55 (s, 1H), 2.34 (s, 3H), which was consistent with the reported data. 
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Compound 2: 1H-NMR (CDCl3, 400 MHz): δ = 8.72 (s, 1H), 7.87 (d, J = 1.9 Hz, 
1H), 5.61 (s, 1H), 3.84-3.80 (m, 4H), 3.74-3.69 (m, 4H), 2.35 (s, 3H), which was 
consistent with the reported data. 
Compound 3: 1H-NMR (CDCl3, 400 MHz): δ = 8.88 (s, 1H), 7.86 (d, J = 2.2 Hz, 
1H), 5.66 (s, 1H), 3.84-3.79 (m, 4H), 3.67-3.62 (m, 4H), 2.79 (s, 3H), 2.38 (d, J = 
1.0 Hz, 3H), which was consistent with the reported data.  
Compound 4: 1H-NMR (CDCl3, 400 MHz): δ = 8.67 (s, 1H), 7.50 (d, J = 1.9 Hz, 
1H), 5.63 (s, 1H), 5.25-5.18 (m, 1H), 4.63 (d, J = 5.0 Hz, 1H), 3.82 (t, J = 2.9 Hz, 
4H), 3.61 (t, J = 4.2 Hz, 4H), 2.35 (d, J = 1.0 Hz, 3H), 1.63 (d, J = 6.6 Hz, 3H); 
13C-NMR (CDCl3, 100 MHz): δ = 18.1, 22.1, 44.5 (x2), 49.1, 66.4 (x2), 81.1, 
117.4, 122.3, 135.3, 137.3, 147.5, 159.0, 160.2; HRMS (ESI) Calc’d for C15H19N3 
NaO3 (M + Na)
+ : 312.1324; Found: 312.1329. 
Compound 5 (TGX-221): 1H-NMR (CDCl3, 400 MHz): δ = 8.67 (s, 1H), 7.60 (d, 
J = 2.0 Hz, 1H), 7.13 (d, J = 7.4 Hz, 1H), 7.12 (d, J = 6.6 Hz, 1H), 6.68 (t, J = 7.3 
Hz, 1H), 6.48 (d, J = 7.6 Hz, 2H), 5.68 (s, 1H), 5.15 (d, J = 5.6 Hz, 1H), 4.39 (bs, 
1H), 3.81 (t, J = 5.0 Hz, 4H), 3.72-3.62 (m, 4H), 2.26 (d, J = 1.0 Hz, 3H), 1.59 (d, 
J = 6.8 Hz, 3H); 13C-NMR (CDCl3, 100 MHz): δ = 18.3, 22.1, 44.6 (x2), 49.1, 66.6 
(x2), 81.3, 113.2 (x2), 117.6, 122.5, 123.8, 129.2 (x2), 135.4, 137.3, 146.8, 147.5, 
159.1, 160.2; HRMS (ESI) Calc’d for C21H25N4O2 (M + H)
+ : 365.1978; Found: 
365.1975. 
Compound 6: 1H-NMR (CDCl3, 400 MHz): δ = 7.22 (dd, J = 7.4, 7.3 Hz, 2H), 
6.78 (d, J = 7.3 Hz, 1H), 6.69 (d, J = 7.7 Hz, 2H), 3.84 (t, J = 5.1 Hz, 2H), 3.32 (t, 
J = 4.9 Hz, 2H), 3.03 (bs, 2H). 
Compound 7: 1H-NMR (CDCl3, 400 MHz): δ = 8.89 (dd, J = 2.1, 1.1 Hz, 1H), 
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7.87 (d, J = 2.2 Hz, 1H), 5.88 (q, J = 6.8 Hz, 1H), 5.68 (s, 1H), 3.82 (t, J = 5.2 Hz, 
4H), 3.65 (t, J = 5.1 Hz, 4H), 3.16 (s, 3H), 2.39 (d, J = 0.9 Hz, 3H), 1.88 (d, J = 
6.8 Hz, 3H); HRMS (ESI) Calc’d for C16H22N3O5 S (M + H)
+ : 368.1280; Found: 
368.1276. 
Compound 8 (BL05): 1H-NMR (CDCl3, 400 MHz): δ = 8.70 (s, 1H), 7.45 (s, 
1H), 7.22 (d, J = 8.6 Hz, 1H), 7.20 (d, J = 8.5 Hz, 1H), 6.86 (d, J = 8.2 Hz, 2H), 
6.76 (t, J = 6.9 Hz, 1H), 5.64-5.60 (m, 1H), 5.59 (s, 1H), 3.63-3.57 (m, 4H), 3.54 
(t, J = 6.0 Hz, 2H), 3.44 (t, J = 5.6 Hz, 2H), 3.41-3.35 (m, 4H), 2.34 (s, 3H), 1.62 
(d, J = 7.0 Hz, 3H); 13C-NMR (CDCl3, 100 MHz): δ = 16.9, 18.4, 44.4 (x2), 47.3, 
52.3, 60.0, 66.5 (x2), 81.3, 114.2 (x2), 117.8, 121.7, 124.3, 129.2 (x2), 135.5, 
136.5, 148.0, 148.2, 159.0, 160.1; HRMS (ESI) Calc’d for C23H29N4O3 (M + H)
+ : 
409.2240; Found: 409.2229. 
BL05-PA: 1H-NMR (CDCl3, 400 MHz): δ = 8.71 (s, 1H), 7.42 (d, J = 1.8 Hz, 
1H), 7.23 (d, J = 8.7 Hz, 1H), 7.21 (d, J = 8.7 Hz, 1H), 6.81 (d, J = 8.2 Hz, 2H), 
6.74 (t, J = 7.2 Hz, 1H), 5.61 (s, 1H), 5.60-5.57 (m, 1H), 4.16-4.09 (m, 1H), 4.00-
3.93 (m, 1H), 3.67-3.59 (m, 5H), 3.58-3.49 (m, 1H), 3.41 (t, J = 4.9 Hz, 4H), 2.34 
(d, J = 0.9 Hz, 3H), 2.28 (t, J = 7.5 Hz, 2H), 1.66 (d, J = 7.2 Hz, 4H), 1.61 (t, J = 
7.2 Hz, 2H), 1.35-1.22 (bs, 23H), 0.90 (t, J = 7.0 Hz, 3H); 13C-NMR (CDCl3, 100 
MHz): δ = 14.1, 17.5, 18.4, 22.7, 24.9, 29.2, 29.3, 29.4 (x2), 29.5 (x2), 29.6 (x2), 
29.7(x2), 31.9, 34.2, 44.0, 44.4 (x2), 51.8, 61.8, 66.5 (x2), 81.3, 113.1 (x2), 117.4, 
121.7, 124.2, 129.3 (x2), 135.7, 136.0, 147.7, 147.9, 159.0, 160.1, 173.7; HRMS 
(ESI) Calc’d for C39H59N4O4 (M +H)
+ : 647.4536; Found: 647.4528. 
BL05-HA: 1H-NMR (CDCl3, 400 MHz): δ = 8.71 (s, 1H), 7.42 (d, J = 1.8 Hz, 
1H), 7.23 (d, J = 8.8 Hz, 1H), 7.22 (d, J = 8.7 Hz, 1H), 7.21 (d, J = 8.7 Hz, 1H), 
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6.81 (d, J = 8.2 Hz, 2H), 6.74 (t, J = 7.2 Hz, 1H), 5.61 (s, 1H), 5.60-5.57 (m, 1H), 
4.17-4.09 (m, 1H), 4.00-3.93 (m, 1H), 3.70-3.58 (m, 5H), 3.41 (t, J = 4.9 Hz, 4H), 
2.34 (d, J = 0.9 Hz, 3H), 2.28 (t, J = 7.4 Hz, 2H), 1.66 (d, J = 7.0 Hz, 3H), 1.64-
1.58 (m, 1H), 1.38-1.26 (m, 5H), 0.91 (t, J = 6.8 Hz, 3H); 13C-NMR (CDCl3, 100 
MHz): δ = 13.9, 17.4, 18.4, 22.3, 24.6, 31.3, 34.1, 44.0, 44.4 (x2), 51.8, 61.8, 
66.5 (x2), 81.3, 113.1 (x2), 117.4, 121.7, 124.2, 129.3 (x2), 135.7, 136.0, 147.7, 
147.9, 159.0, 160.1, 173.7; HRMS (ESI) Calc’d for C29H39N4O4 (M + H)
+ : 
507.2971; Found: 507.2955. 
2.3.2 SLN characterization 
   SLN prepared by thin film, hot homogenization and solvent precipitation 
methods were compared. The solid lipid Compritol® 888 ATO, a glycerol 
behenate, was used. Particle sizes were measured by dynamic light scattering 
(Table 1). We found that the solvent precipitation method gave the smallest 
particle. In addition, the particle size also can be reduced by increasing 
surfactant ratio. 
The influence of the lipid was also studied, using the solvent precipitation 
method.  The melting point of Compritol® 888 ATO and Dynasan® 114 are 69 - 
74 °C and 56 -57 °C, respectively. The average particle size of SLN dispersion 
can be reduced to 87.5 ± 2.3 nm by using a lower melting point lipid. For 20 % 
(w/w) TGX-221 loaded Compritol® 888 ATO SLN, encapsulation efficiency was 
approximately 95 % (Table 2). 
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Table 1. Particle sizes of empty SLN prepared by different formulation methods and 
different lipid/surfactant ratios.     
Formulation 
Size (nm)  
(mean ± SD) 
Thin Film 
Lipid : Surfactant (3:1) 475.3 ± 59 
Lipid : Surfactant (2:1) 414.5 ± 12.6 
Hot Homogenization 
Lipid : Surfactant (3:1) 312.5 ± 12.5 
Lipid : Surfactant (2:1) 235.2 ± 13.6 
Solvent Precipitation Lipid : Surfactant (2:1) 107.8 ± 0.5 
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Table 2. Encapsulation efficiencies of TGX-221 loaded nanoparticles prepared by 
different formulation methods. 
Formulations Encapsulation Efficiency 
SLN Compritol® 888 ATO w/ 10 % TGX-221 95.3 % 
SLN Compritol® 888 ATO w/ 20 % TGX-221 92.5 % 
SLN Dynasan 114 w/ 10 % TGX-221 89.9 % 
SLN Dynasan 114 w/ 10 % TGX-221 86.2 % 
NLC Comprotol® 888 ATO w/ 10 % TGX-221 95.4 % 
NLC Apifil® w/ 10 % TGX-221 91.2 % 
PEG-PCL Micelle w/ 10 % TGX-221 87.5 % 
PLGA (0.24 dl/g) F-127 w/ 5 % TGX-221 39.1 % 
PLGA (0.69 dl/g) F-127 w/ 5 % TGX-221 51.7 % 
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    The release kinetics of SLNs prepared by solvent precipitation method with 
different lipid and drug loading degrees were evaluated (Fig. 2). We found that 
different lipid showed similar release profiles and the drug loading degree did not 
affect the release half-lives. 
2.3.3 NLC characterization 
Particle sizes and zeta potentials of NLCs prepared by different combinations 
are shown in Table 3.  We showed that the particle made by Compritol® 888 ATO 
was more stable compared to that of Apifil®. However, the particle sizes of 
different lipid matrix NLCs were approximately the same. In addition, the particle 
sizes and zeta potentials were not significantly changed between empty and drug 
loaded particles.  
The in vitro release study indicated that different lipid and surfactant 
combinations did not show significantly influence on TGX-221 release (Fig. 3). 
However, compared to SLN, NLC improved drug release half-lives from 2-3 h to 
5-6 h. 
2.3.4 PLGA nanoparticle characterization 
The particle sizes of PLGA nanoparticles made with PLGAs of different 
inherent viscosities are shown in Table 4. We found that the surfactant type 
significantly influenced on particle size. The particle size was also sensitive to the 
inherent viscosity of PLGA. The PLGA nanoparticles stabilized by PVA were the 
smallest. In addition, PVA stabilized particles showed a longer in vitro release 
half-life compared to the particles stabilized by Pluronic® F-127 (Fig. 4).  
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Fig. 2: In vitro release profiles of TGX-221 loaded SLNs made with different lipids and 
different drug loading degree. 
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Table 3: Particle sizes and zeta potentials of empty and drug loaded NLCs (mean ± 
SD). 
Formulation Size (nm) 
Zata Potential 
(mV) 
Empty 
particle 
888 ATO + S108 150.6 ± 1.7 -48.97 ± 2.72 
888 ATO + α-tocopherol 171.3 ± 11.4 -42.97 ± 2.05 
Apifil + S108 150.6 ± 4.7 -28.2 ± 4.43 
w/ 10% 
TGX221 
888 ATO + S108 169.7 ± 3.6 -50.48 ± 3.89 
Apifil + S108 165.6 ± 2.3 -33.5 ± 0.91 
Apifil + 90H 129.3 ± 0.1 -20.77 ± 0.31 
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Fig. 3: In vitro release profiles of NLC prepared by different lipid and surfactant 
combinations. 
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Table 4: Particle sizes measurements of NLC stabilized by different surfactants. 
 
 
 
 
 
 
 
 
Formulation 
Size (nm) 
(mean ± SE) 
PLGA (1.05 dl/g) Pluronic® F-127 168.5 ± 1.5 
PLGA (0.69 dl/g) Pluronic® F-127 181.2 ± 2.7 
PLGA (0.23 dl/g) 
Pluronic® F-127 171.7 ± 2.6 
Polyvinyl alcohol (PVA) 119.1 ± 1.9 
Poly (acrylic acid) (PAA) 212.5 ± 5.6 
PVA: PAA (50:50) 180.4 ± 3.1 
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Fig. 4: In vitro release profiles of different PLGA nanoparticles.  
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2.3.5 PEG-PCL micelle preparation and characterization 
The N3-PEG-PCL block copolymer was synthesized by a ring opening reaction. 
1H-NMR spectra showed two main peaks at 3.67 (-OCH2CH2) and 4.08 (-
OCH2CH2CH2CH2CH2CH2CO-) that correspond to PEG and PCL, respectively. 
The molecular weight of N3-PEG-PCL copolymer determined by 
1H-NMR was 
5,800:5,800 and the polydispersity of this polymer measured by GPC was 1.10. 
The CMC was determined to be 300 nM using the pyrene incorporation assay.  
Based on Gibb’s free energy of micellization, the nanomolar CMC of PEG-PCL 
copolymer indicated that the micelle had high thermodynamic stability. For 10 % 
(w/w) BL05-HA loaded PEG-PCL micelles, the encapsulation efficiency was 74.5 
± 4.6 %. 
The N3-PEG-PCL micelles were prepared using a solvent displacement 
method. The PCL block served as a hydrophobic core of the micelle and 
physically entrapped the poorly water soluble anticancer drug into the micelle. 
GPC was used to confirm the formation of PEG-PCL micelles. PEG-PCL micelles 
are known to be stable when diluted below the CMC during GPC analysis, which 
reflects a high kinetic stability against dissociation (32). The micelles’ 
hydrodynamic diameter from DLS with Gaussian volume weighting was 
approximately 50 nm (Table 1), which is suitable for intravenous administration 
and extravasation in tumors (33).  
2.3.6 Conjugation of PSMAa10 to PEG-PCL micelles 
    The alkyne modified aptamer, PSMAa10, was confirmed by ESI-MS ([M+Na]+ 
= 18,928.0). The alkyne modified PSMAa10, was conjugated to the azide end 
group of the PEG-PCL copolymer by the Huisgen cycloaddition click reaction. 
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The conjugation efficiency was determined by quantifying the unconjugated 
ligand remaining in the supernatant. The amount of PSMAa10 conjugated to the 
N3-PEG-PCL micelle surface increased with increasing reaction time: 1 h, 0.017 
± 0.005 (yield: 14.2 %); 3 h, 0.103 ± 0.010 (yield: 20.6%); 5 h, 0.123 ± 0.015 
(yield: 24.6 %) mg PSMAa10 / mg N3-PEG-PCL. Since precipitation occurred 
after 5-h, the Click reaction time was controlled at 3 h. The conjugation of 
PSMAa10 to the micelle’s surface was examined by agarose gel electrophoresis 
(data not shown). The near infrared fluorophore IR-820 was functionalized with 
an alkyne by TEA buffered condensation with 1-amino-3-butyne. The successful 
conjugation was confirmed by ESI-MS. The micelle surface also was modified 
with IR-820 by click reaction. The IR-820 conjugated micelles had a maximum 
absorption wavelength of 675 nm and an emission wavelength of 745 nm. 
2.3.7 Characterization of conjugated PEG-PCL micelles 
Particle sizes of different micelle formulations were determined by dynamic 
light scattering (Table 5). All of the formulations had particle sizes that were 
smaller than 100 nm and the in vitro release half-lives were improved by 
encapsulating more hydrophobic prodrugs. The sizes of all of the nanoparticle 
formulations were smaller than 100 nm, which is suitable for intravenous 
application. The in vitro release half-lives of TGX-221, BL05, BL05-HA and BL05-
PA were investigated at simulated in vivo conditions using a bath at pH 7.4 and 
37 °C (Table 5). In addition, the release half-lives of TGX-221 and its analog, 
BL05, from PEG-PCL micelles were identical, which is likely due to the similar 
lipophilicity of the two compounds. TGX-221 had a calculated logPo/w of 2.14 ± 
0.68 and BL05 was 1.81 ± 0.67 (ALogPS 2.1, http://www.vcclab.org). The more 
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hydrophobic ester prodrugs, BL05-HA (logPo/w  4.15 ± 0.31) and BL05-PA (logPo/w 
8.42 ± 0.83), had much longer release half-lives of 5 and 6.5 days in PEG-PCL 
micelles, respectively. The prodrugs tended to stay in the hydrophobic PCL core 
of the micelle, and they were protected from hydrolysis in the hydrophobic core 
due to limited penetration of water. The aptamer conjugated micelle was larger 
than the non-targeted micelle, and the conjugation of IR-820 was confirmed by 
observing the increased Stokes shift of fluorescent dye. The Stokes shift of IR-
820 increased after conjugation to the micelle surface due to electromagnetic 
retardation (34). 
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Table 5: Characterization of different drug loaded PEG-PCL micelles.         
 
Size (nm) 
(Mean ± SD) 
In vitro 
Release Half-life 
Empty Micelle 27.6 ± 0.2 - 
PSMA-targeted Micelle 40.5 ± 0.8 - 
TGX-221 Loaded Micelle (5% w/w) 54.5 ± 0.3 <1h 
BL05 Loaded Micelle (5% w/w) 59.8 ± 2.2 < 1 h 
BL05-HA Loaded Micelle (5% w/w) 49.9 ± 0.5 5 days 
BL05-PA Loaded Micelle (5% w/w) 29.9 ± 0.1 6.5 days 
BL05-HA Loaded PSMA-targeted Micelle 58.8 ± 0.9 - 
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2.3.8 In vitro cytotoxicity studies  
The IC50s of TGX-221, BL05 and BL05-HA were determined in DU145, PC3 
and LNCaP cells (Table 6). BL05-PA was not soluble in PBS with 1 % DMSO, 
and it was not tested further. TGX-221, BL05 and BL05-HA showed selective 
cytotoxicity to LNCaP cells, which may be due to the deficiency of PTEN in this 
cell line and the accumulation of PIP3 in the cells. A Western blot was performed 
to determine if both TGX-221 and BL05 are involved in the same cell signaling 
pathway that contributes to the selective cytotoxicity. As demonstrated by 
Western blot, TGX-221 and BL05 inhibited phosphorylation of Akt (Fig. 5), which 
in turn indicated the inhibitor of PI3K activity. 
The cytotoxicity of empty micelles, PSMA-targeted empty micelles, IR-820-
labeled empty micelles and IR-820-labeled PSMA-targeted micelles was 
examined in DU145 prostate cancer cells (Fig. 6). The drug free targeted 
micelles did not inhibit cell growth. However, the dye-labeled micelles did inhibit 
cell growth, so they were not characterized further in vivo. 
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Table 6: IC50s of TGX-221, BL05 and BL05-HA in different prostate cancer cell lines. 
All of the drugs showed selective cytotoxicity to PSMA-positive LNCaP cells (*: p < 0.05; 
**: p < 0.01). 
 
TGX-221 (μM) 
(Mean ± SE) 
BL05  (μM) 
(Mean ± SE) 
BL05-HA  (μM) 
(Mean ± SE) 
DU145 35.6 ± 0.12 32.4 ± 0.67** 52.5 ± 0.15** 
PC3 18.2 ± 0.85 23.4 ± 0.74** 21.8 ± 0.66** 
LNCaP 3.98 ± 0.18 4.036 ± 0.11 3.19 ± 0.12* 
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Fig. 5: Western blot analysis of Akt phosphorylation on Ser473 and total Akt protein 
levels with different treatments. Both TGX-221 and BL05 showed inhibitory effects 
on the phosphorylation of Akt.  
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Fig. 6: Cytotoxicity of empty micelles in DU145 cells (Mean ± SD). 
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2.3.9 Micelle formulation effects on cellular uptake of the drug 
The DU145 cells were treated with BL05-HA in DMSO and BL05-HA loaded in 
non-targeted micelles. The solubility of BL05-HA in 5 % DMSO was determined 
to be 32.35 µg/mL (49.86 µM). After a 12-h treatment, the cell culture medium 
was analyzed for extracellular drug content by HPLC, and the drug uptaken by 
the cells was quantified (Fig. 7). Micelle formulations significantly improved the 
cellular uptake at all concentrations, also DMSO was not required to solubilize 
BL05-HA in the micelle formulation. 
 
 
 
 
 
 
 
 
 
 
58 
 
50 25 10 5 1
0.0
0.5
1.0
1.5
Naked Drug
Micelle Forumlation
*
*
*
*
BL05-HA Conc. (M)
A
m
o
u
n
t 
o
f 
d
ru
g
 u
p
ta
k
e
 (

g
)
Fig. 7: The micelle formulation improved DU145’s uptake of BL05-HA (Mean ± SD). (*: 
p < 0.001) 
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2.3.10 PSMAa10 targeting improved cellular uptake of both micelles and drug by 
PSMA-positive cells 
LNCaP cells (PSMA +) were treated with PSMA-targeted and IR-820-labeled 
micelles with increasing substitutions of the aptamer. The micelle uptake was 
estimated by the relative fluorescence intensity of the IR-820. The fluorescence 
increased with increasing aptamer substitution: 1 %, 325 ± 103.410; 2.5 %, 
574.554 ± 33.614; 5 %, 704.055 ± 73.235 and 10 %, 945.311 ± 145.445 RFU. 
Confocal microscopy was used to examine if PSMA targeting can improve the 
micelle uptake by PSMA presenting cells. The aptamer did not improve the 
micelle uptake in the PSMA-negative PC3 cells. However, in the PSMA-positive 
LNCaP cells, we detected more fluorescence signal in cells treated with PSMA-
targeted micelles (Fig. 8). The uptake was then quantified with a fluorescence 
plate reader. The fluorescence signal was significantly higher in PSMA-positive 
cells (LNCaP) treated with PSMA-targeted micelles. However, in PSMA-negative 
PC3 cells, the fluorescence was not enhanced by addition of PSMA to the 
micelles (Fig. 9). 
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Fig. 8: Fluorescence imaging study of cell uptake of fluorescent PSMA-targeted 
micelles in PSMA-positive LNCaP cells. (A) PC3 cells treated with non-targeted 
micelles; (B) PC3 cells treated with PSMA-targeted micelles; (C) LNCaP cells 
treated with non-targeted micelles; (D) LNCaP cells treated with PSMA-targeted 
micelles.  
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Fig. 9: Uptake of micelles by (a) PC3 cells; and (b) DU145 cells (Mean ± SD). (*: p < 
0.05; **: p < 0.01) 
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The effect of PSMA-targeting of micelles on the cellular uptake of BL05-HA was 
examined in both DU145 (PSMA -) and LNCaP (PSMA +) cells (Fig. 7). PSMA-
targeted micelles significantly improved the drug uptake in PSMA-positive LNCaP 
cells but not PSMA-negative DU145. In addition, BL05-HA formulated in PSMA-
targeted micelles significantly reduced LNCaP cell viability compared to the naked 
drug, whereas BL05-HA in non-targeted micelles was no more effective than the 
naked drug. In PSMA negative cells, this significant effect was not observed (Fig. 11) 
(p > 0.05). 
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Fig. 10: PSMA-targeted micelles improved drug uptake by PSMA positive cells. 
Drug uptake by (a) PSMA-negative DU145 cells and (b) PSMA-positive LNCaP cells 
treated with targeted or non-targeted formulations (Mean ± SD). (*: p < 0.001) 
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Fig. 11: IC50s of different formulations of BL05-HA in LNCaP and DU145 cells (Mean ± 
SE). (*: p < 0.01; ^: p > 0.05) 
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2.3.11 Pharmacokinetic evaluation 
The pharmacokinetics of naked BL05-HA and BL05-HA formulated in PSMA-
targeted micelles were compared in male Balb/c mice (n = 3). The initial drug 
plasma concentration (C0) of the micelle formulation was 1.42-fold greater than 
the naked drug (Fig. 12). The plasma concentration of BL05 delivered by PSMA-
targeted micelles was higher than the naked drug at all time points. A two-
compartment pharmacokinetic model was selected to describe the biexponential 
nature of the pharmacokinetics disposition of PEG-PCL micelle formulation; 
whereas one-compartment model was used in BL05-HA naked drug and the 
related pharmacokinetic parameters are listed in Table 7. The area under the 
plasma concentration time curve (AUC0-24h) of the micelle formulation was 2.27-
fold greater than that of the naked drug and the concomitant total body clearance 
was 6.2-fold lower. 
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Fig. 12: Plasma BL05 concentration versus time disposition (Mean ± SD) (n = 3). 
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Table 7: Pharmacokinetic parameters after i.v. administration of BL05-HA loaded 
PSMA-targeted micelles and naked BL05-HA (Mean ± SD) (n = 3). (*: p < 0.05; **: p < 
0.01; ***: p < 0.001) 
Parameters Unit 
PSMA-targeted 
Micelle 
Naked BL05-HA 
Vd L·kg
-1 15.76 ± 2.01** 21.71 ± 2.42 
C0 µg·mL
-1 1.95 ± 0.27* 1.41 ± 0.17 
AUC0-24h µg·h·mL
-1 7.93 ± 0.45*** 3.60 ± 0.21 
k h-1 0.22 ± 0.02 0.337 ± 0.03 
k12 h
-1 0.71 ± 0.21 - 
k21 h
-1 0.98 ± 0.79 - 
Cl mL·min-1·kg-1 3.41 ± 0.25* 7.22 ± 0.38 
t1/2 h 7.84 ± 2.13** 2.08 ± 0.20 
MRT h 9.89 ± 1.89** 3.01 ± 0.29 
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2.3.12  Efficacy study in xenograft models 
Tumor volume was calculated by length × width × 0.5 and tumor growth curves 
were generated by plotting the relative fold value of tumor volume at each time 
point comparing to their initial volume (set to value 1). As shown in Fig. 13, 
compared to the control, both PEG-PCL micelle-delivered TGX-221 analog BL05 
and the naked BL05 significantly suppressed tumor growth in four cell lines-
derived xenografts. The asterisk indicates a significant difference compared to 
the control (ANOVA analysis, p < 0.01). 
Paraffin-embeded tumor sections from 22RV1 xenografts were subjected to 
immune-fluorescent staining with anti BrdU antibody followed by FITC-
conjugated secondary antibody. Tumor sections were counter-stained with 
nuclear acid dye DAPI. Microscopic images were taken using Olympus 
fluorescent microscope (magnficaiton, 200×). As shown in Fig. 14, a dramatic 
decrease of immunofluorescent positive cells compared to the control group, 
indicating PEG-PCL micelle delivered BL05 suppressed tumor cell proliferation in 
xenograft models. 
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Fig. 13: PSMAa10-conjugated BL05-loaded PEG-PCL-micelles abolish tumor 
growth in prostate cancer xenograft models.  
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Fig. 14: BL05 loaded micelle reduced BrdU labeling in xenograft tumors.  
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2.4 Discussion 
Prostate cancer is by far the most commonly diagnosed cancer among western 
males. Most anticancer drugs are administered intravenously or orally to achieve 
systemic distribution and the non-specific uptake of anticancer drugs may cause 
damage to healthy, rapidly dividing cells such as bone marrow and hair (35, 36). 
Nanoparticles can passively or actively target tumor tissue and minimize the side 
effects of conventional chemotherapies such as sexual dysfunction, cardiac toxicity, 
gastrointestinal damage, and neurotoxicity (37). The leaky endothelial vasculature 
of tumor tissues and the size properties of nanoparticles play a significant role in 
their passive targeting (38), due to the EPR effect. Improved targeting can be 
achieved by decorating the nanoparticle surface with a tumor specific targeting 
molecule such as a monoclonal antibody or nucleic acid (39). The tumor specific 
targeting molecules can bind to tumor cells and increase the intracellular 
concentration of the drug by receptor-mediated endocytosis. In this study, we 
formulated a prostate cancer cell-targeted nanocarrier that can enhance the efficacy 
of an encapsulated anticancer drug against prostate cancer cells and also optimize 
the pharmacokinetic disposition of the drug in a mouse model because of the 
encapsulated carrier. We targeted the carriers to prostate cells with the PSMA 
aptamer because this small ligand has nM affinities for the PSMA receptor, which is 
ubiquitous to clinical prostate cancers (40). We conjugated the ligand to pre-formed 
micelles. This approach is expected to result in a more homogenous distribution of 
the ligands among the nanoparticles than other approaches such as attaching 
ligands to the monomers before formation or drug encapsulation. The resulting 
triazole linker is also more resistant to hydrolytic and enzymatic cleavage than 
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esters or amides formed by carbodiimide chemistries.  
TGX-221 showed selective cytotoxicity against LNCaP cells, which was 
consistent with a previous report (13). TGX-221 and its analog, BL05, showed 
similar toxicity in different prostate cancer cell lines, and Western blotting confirmed 
their inhibitory effects on phosphorylation of Akt in LNCaP cells. The modification of 
the aniline nitrogen did not affect the drug activity significantly, which is possible if 
only the morpholinechromone ring system and aniline structure contribute to the 
binding to PI3K beta subunit (41). 
SLN is a novel approach to oral and parenteral drug delivery systems. Biological 
lipids have minimum carrier cytotoxicity, and the solid state of the lipid core permit 
better controlled drug release due to increase mass transfer resistance. SLN 
possess a solid lipid core matrix that can solubilize lipophilic molecules. The lipid 
core has to be stabilized by surfactants to reduce surface tension. This approach 
holds great promise for attaining bioavailability enhancement along with site specific 
drug delivery. In this study, a burst release of the drug was observed. This indicated 
that TGX-221 didn’t incorporate to the lipid core very well. There are also some 
limitations of using SLN as a drug delivery carrier such as relatively low loading 
capacity and potential expulsion of the drug during storage. In addition, the highly 
purified lipid can crystallize in a more perfect crystalline lattice that leaves little room 
for the incorporation of the drugs. 
To overcome the limitations of SLN, the concept of NLC was introduced. NLC 
possess many imperfections, thus increasing drug loading capacity and minimizing 
or avoiding drug expulsion during storage. In general, a solid lipid is mixed with a 
liquid lipid (oil). This blend is used to produce the lipid particles that are still solid at 
74 
 
temperatures up to about 40 °C. Our study showed that by using NLC, the in vitro 
release of the drug was partially improved. Nevertheless, the formulation was still 
not good enough for being used as a sustained and controlled release drug delivery 
carrier for TGX-221.  
Synthetic polymers have been extensively researched as colloidal materials for 
nanoparticle production designed for drug delivery. PLGA polymer has been 
approved by FDA for human therapy. One commercially available drug delivery 
device using PLGA is Lupron Depot® for the treatment of advance prostate cancer. 
We tried to encapsulate TGX-221 to PLGA nanoparticles and we found that TGX-
221 still could not be retained in this drug delivery carrier; therefore, a prodrug 
strategy was pursued.  
Drug interaction and association with the hydrophobic core of the micelle can 
influence a drug’s release rate (42). Both TGX-221 and BL05 did not stay in the 
hydrophobic core of PEG-PCL micelles, which may be due to the amphiphilic nature 
of these molecules. Therefore, the hydrophobic character of the drug was modified 
by the addition of hydrophobic fatty esters. The fatty acid prodrugs are susceptible 
to intra- and extra-cellular esterases and hydrolysis, so the parent drug is expected 
to reform rapidly after the drug is released from micelles. This addition increased 
the encapsulation efficiency leading to the postulation that the long carbon chain 
may also decrease the release rate due to the drug’s more favorable interaction to 
the hydrophobic core (43, 44).  
The in vitro cytotoxicity study showed that both PSMA-targeted and non-targeted 
empty micelles were not toxic to DU145 cells. This was expected since both PEG 
and PCL polymers are already FDA approved for use in humans and PSMAa10 is 
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made of a single stranded oligonucleotide. However, inhibitory effects were 
observed with IR-820 labeled PEG-PCL micelles. The toxic effect came from the 
dye, IR-820, which was reported to significantly inhibit cell growth at concentrations 
greater than 5 µM (34). Therefore, the IR-820 labeled non-targeted and targeted 
micelles were only used for examining delivery efficiency and not for further in vivo 
characterization.  
Due to the change of partition and diffusion coefficients, BL05-HA may have lower 
membrane permeability compared to its parent drug, BL05, and TGX-221. Thus, the 
passive diffusion rate of the BL05-HA naked drug to the cells could be lower. The 
micelle formulation significantly improved cellular uptake of BL05-HA, which is 
consistent with the enhanced cellular uptake of drugs internalized witin PEG-PCL 
micelles (45). 
We found that encapsulating BL05-HA within PSMA targeted PEG-PCL micelles 
increased cytotoxicity in LNCaP cells (PSMA positive) but not in PC3 cells (PSMA 
negative). This can be explained by the enhanced cellular uptake of the carrier by 
PSMA-positive cells through a receptor-mediated pathway. Cellular uptake of the 
naked drug is driven by a concentration gradient. After equilibrium is established, no 
more drugs can enter into the cells. The PEGylated surface of the micelles reduces 
interaction with the cell surface. Therefore, the cytotoxicities of naked drug and the 
untargeted drug-loaded micelles in LNCaP and PC3 cells were not significantly 
different. In PSMA positive cells, the receptor mediated transport of PSMA-targeted 
micelles improved drug delivery into cells, significantly enhancing cytotoxicity. Since 
the expression of PSMA on PSMA-negative cells was extremely low, the effect of 
PSMA-targeting was not significant (p > 0.05). 
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A two-compartment model was used to describe the pharmacokinetic (PK) 
disposition of the PEG-PCL micelle formulation. The PK profile showed that the 
plasma drug concentration declines biexponentially as the sum of distribution and 
elimination processes. The rapid drug concentration decrease in the initial phase 
was due to the drug’s distribution from the central compartment into the peripheral 
compartments. Drug metabolism and excretion contributed to the gradual decrease 
in the plasma concentration during the beta phase. In the pharmacokinetics study, 
we have shown that the PEGylated micelles can increase the plasma AUC and 
detectable systemic circulation of the drug by avoiding clearance by the 
reticuloendothelial system (RES) and kidneys. The RES consists primarily of 
monocytes and macrophages in the spleen and liver that are responsible for 
clearing molecules bound with serum proteins. The kidneys clear unbound drugs, 
by glomerular filtration, below the renal exclusion limit of ca. 20-60 kDa. Stealth 
nanoparticles surface-modified with PEG can avoid clearance by the RES and 
kidneys, thus they have prolonged circulation half-lives in the plasma (46). This 
approach has been used to optimize pharmacokinetic disposition of nanoparticles 
and enhance drug delivery (46, 47). In this study, the high Vd value of naked BL05-
HA may be due to its high tissue distribution. A rapid total body clearance rate is 
also apparent. The micelle formulation significantly reduced the Vd by minimizing 
non-specific tissue distribution and the drug was consequently retained within the 
vascular system. This could also reduce toxicity to normal tissues by reducing their 
exposure to the drug through non-specific distribution. 
The combination of androgen ablation (hormone therapy) along with early 
detection and surgery has made prostate cancer highly treatable at the initial stage. 
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However, this cancer remains the second leading cause of cancer death among 
American men. Our collaborator has demonstrated that the PI3K p110beta isoform, 
a major cellular signaling molecule, is critical for prostate cancer progression in cell 
culture models and mouse xenograft models (48).  
In animal subcutaneous xenograft experiments, the solvent PPG, naked TGX-221 
analog BL05 and BL05 prodrug (BL05-HA) loaded micelles were used. The 
maximum tolerable dose of BL05 as a naked drug in PPG or encapsulated in a 
PSMAa10-conjugated micelles were given twice a week by tail vein injection. Our 
data revealed that PSMAa10 conjugation of the BL05-HA completely abolished 
tumor growth of prostate xenograft tumors derived from all four prostate cancer cell 
lines, both androgen-responsive and non-responsive cell lines. Similarly, naked 
BL05 treatment also blocked tumor growth in LAPC-4 and C4-2-derived xenografts, 
although in animals with LNCap or 22RV1-derived xenografts, a slight increase of 
tumor volume was noticed after 3 weeks. The immunofluorescent staining revealed 
a reduced anti-BrdU labeling in PEG-PCL micelle treated xenografts compared to 
tumors in the control or naked BL05 groups. These data strongly suggested that 
TGX-221 and its analog possess a potent anti-tumor effect and PSMA-mediated 
targeting greatly enhances its potency over naked drugs.  
2.5 Conclusions 
    The synthesis of TGX-221, the analog BL05, and the BL05-HA and BL05-PA 
prodrugs were successfully accomplished. Both TGX-221 and its analog BL05 had 
an inhibitory effect on the phosphatation of PIP3 in PTEN-deficient LNCaP cells. 
Compared to SLN, NLC and PLGA nanoparticles, micelle formulation gave the 
smallest particle size, which is better for intravenous administration. Encapsulation 
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of BL05-HA in PEG-PCL micelles resulted in sustained release over several days. 
In vitro, we have shown that micelles targeted with PSMAa10 and loaded with 
BL05-HA significantly inhibits the growth of PSMA-positive prostate cancer cells, but 
not PSMA-negative cells. In vivo pharmacokinetics demonstrated that PSMA-
targeted micelles significantly increased the AUC and decreased the total body 
clearance rate of the drug. Moreover, the PSMA-targeted micelle formulation of 
TGX-221 analog, BL05, significantly suppressed tumor growth in all four cell lines’-
derived xenografts. These findings suggested that PSMA-targeted micelles are a 
promising drug delivery vehicle for developing PI3-kinase inhibitor treatments of 
PSMA positive prostate cancers. 
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Chapter 3 
Pharmacokinetic Evaluation of a DSPE-PEG2000 Micellar Formulation of 
Ridaforolimus in Rat 
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3.1 Introduction 
Ridaforolimus, also known as deforolimus, AP-23573, and MK8669, is a non-
prodrug rapamycin analog (Fig. 1A). It is a large lipophilic (MW: 990 g/mol; XlogP: 
5.9) carboxylic lactone-lactam macrolide antibiotic with potent anti-proliferative and 
immunosuppressive effects. Ridaforolimus inhibits the mammalian target of 
rapamycin (mTOR), a serine/threonine kinase that is expressed throughout most 
mammalian cells and that is involved in a variety of cell signaling cascades (1). 
Inappropriate activation of mTOR has been implicated in the pathogenesis of a 
range of cancers and can account for tumor proliferation and growth (1). 
Ridaforolimus has been shown to inhibit mTOR and has demonstrated anti-
proliferative activity against several cancer types in vitro and in vivo (2). 
Ridaforolimus is currently undergoing numerous clinical trials for a range of 
cancers both as a monotherapy and in combination with other chemotherapeutics 
including a Phase III clinical trial for metastatic soft-tissue and bone sarcoma. 
Formulations being evaluated in these clinical trials include an intravenous 
formulation given as an infusion and an oral formulation.  The pharmacokinetic 
results from these studies suggest ridaforolimus follows non-linear kinetics following 
oral and intravenous administration as indicated by non-linear increases in area 
under the curve (AUC) and concentration maximum (Cmax) with increases in dose 
(3). Changes in clearance (Cl) and volume of distribution at steady state (Vss) are 
also reported to change with dose (3). It has been suggested that this nonlinearity is 
consistent with saturation of the red blood cell compartment which contains a 
substantial amount of FKBP-12, the binding protein of ridaforolimus and other  
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Fig. 1: Chemical structure of (A) ridaforolimus and (B) DSPE-PEG2000 
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rapamycin analogs (4). This strong partitioning of ridaforolimus to the red blood cell 
compartment may hinder the accessibility of ridaforolimus into solid tumor sites (5). 
Ridaforolimus and other derivatives of rapamycin including temsirolimus and 
everolimus differ from rapamycin at the C-42 position. In the case of ridaforolimus, 
the C-42 position consists of a dimethylphosphinate substitution, which increases 
the aqueous solubility of ridaforolimus (ca. 200 μg/mL) in comparison to rapamycin 
(ca. 2.6 μg/mL). Although improved in relation to rapamycin, the solubility of 
ridaforolimus is still poor and has likely hindered development of clinical intravenous 
formulations. This cannot be verified, however, as the only formulation information 
published to our knowledge includes that of animal studies where ridaforolimus was 
solubilized in a complicated vehicle of dimethyl acetamide/polysorbate 
80/polyethylene glycol-400/water (10/10/40/40 v/v/v/v) (6). 
Further increasing the solubility of ridaforolimus through the use of nanocarrier 
technology may decrease the amount of ridaforolimus that partitions to the 
erythrocyte compartment and thereby allow for easier prediction of pharmacokinetic 
parameters. A specific class of nanocarriers that has a large solubilization capacity 
for poorly water soluble molecules are the pegylated phospholipid (PPL) micelles 
(7). These self-assembled micelles are capable of solubilizing a wide range of 
hydrophobic molecules, and they are a potential tool for the safe formulation and 
delivery of antitumor agents to tumors without the inclusion of potentially harmful 
surfactants and excipients (5, 7, 8). Due to their nanoscopic dimensions (typically < 
70 nm), PPL micelles can leave leaky vasculature, accumulating in tumors via the 
enhanced permeability and retention effect (EPR), where they remain due to poor 
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lymphatic clearance (7). An outer coat of poly(ethylene glycol) (PEG) imparts 
“stealth” characteristics to micelles, allowing them to circulate for long periods of 
time and avoid the mononuclear phagocyte system (MPS). These effects potentially 
reduce non-specific toxicities of the chemotherapeutic.  Therefore, encapsulation of 
ridaforolimus in a micelle nanocarrier may limit its systemic toxicities specifically its 
dose-limiting toxicity of mucositis (3). 
Previous investigations have confirmed that micelle formulations of poly(ethylene 
glycol)-block-poly(caprolactone) (PEG-b-PCL) can substantially increase the 
solubility and circulation time of rapamycin, while also greatly reducing the non-
specific toxicity (5). We hypothesize that encapsulation of ridaforolimus in the PPL 
micelle polymer 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-
poly(ethylene glycol 2000) (DSPE-PEG2000) may allow for improved solubility while 
limiting the partition to erythrocytes. DSPE-PEG2000 (Fig. 1B); was chosen due to its 
promising kinetic and thermodynamic stability and biocompatibility DSPE-PEG2000 
has received regulatory approval in the US and/or Europe in three formulations of 
doxorubicin (Doxil, LipoDox and Thermodox). Herein, we report the 
pharmacokinetics of a DSPE-PEG2000 formulation of ridaforolimus in rats. To our 
knowledge, this is the first report of the pharmacokinetics of ridaforolimus in rats and 
the first attempt to solubilize ridaforolimus in any type of nanocarrier. 
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3.2 Materials and Methods 
3.2.1 Chemical and reagents 
    Ridaforolimus was purchased from LC Labs (Woburn, WA, USA). 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-
2000] (DSPE-PEG2000) copolymer was purchased from Avanti Polar Lipids 
(Alabaster, Alabama, USA). HPLC-grade methanol and water were purchased 
from J.T. Baker (Philipsburg, NJ, USA). Other chemicals were of analytical 
grade. Healthy male Sprague-Dawley rats were obtained from Simonsen Labs 
(Gilroy, CA, USA). Ethical approval for animal experiments was obtained from 
Institutional Animal Care and Use Committee of Washington State University. 
3.2.2 Preparation of drug formulations 
Ridaforolimus loaded micelles were prepared by solvent evaporation 
technique. Specifically, ridaforolimus and DSPE-PEG2000 (Avanti Polar Lipids, 
Inc.) were solubilized in 1:1 acetone and methanol. The solution was then added 
in a drop-wise fashion to vigorously stirred ddH2O using a syringe pump. The 
organic solvent was removed by stirring under an air purge. Solutions were then 
filtered through a 0.22-μm polyestersulfone filter to sterilize and remove 
unincorporated drug. Solutions were protected from light and stored at 4 °C until 
administered. 
A control formulation for intravenous administration of ridaforolimus was made 
by dissolving ridaforolimus in ethanol followed by addition to PEG400 to form a 
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final formulation of 1:1 ethanol:PEG. The resulting mixture was vortexed until 
clear and passed through a 0.22-μm polyestersulfone filter. 
Formulation concentrations were determined using a Shimadzu LC-2010A 
(Kyoto, Japan). A Phenomenex® Luna C18 (2) analytical column (250 x 4.6 mm; 5 
μm) was used with UV detection at 290 nm (CA, USA). The mobile phase 
consisted of acetonitrile, water and formic acid (30:70:0.04, v/v/v) that was 
filtered and degassed prior to use with isocratic separation carried out at a flow 
rate of 0.3 mL/min. Hydrodynamic diameters of DSPE-PEG2000 micelles were 
performed using Dynamic Light Scattering (DLS) with a Malvern Nano ZS 
instrument and DTS software (Malvern Instruments Ltd, Malvern, Worcestershire, 
UK). 
3.2.3 Micelle characterization 
The formation of DSPE-PEG2000 micelles was determined by gel permeation 
chromatography (GPC) using a Shimadzu 2010CHT system with 0.8 ml/min 
ddH2O as the mobile phase on a Shodex OHpak-803 HQ column (Showa Denko 
America, NY) thermostated at 40 °C. An evaporative light scattering detector 
(ELSD-LTII, Shimadzu, Lenexa, KS) was used to detect the particles. Narrow 
molecular weight distribution polyethylene glycols (Scientific Polymer Products, 
Ontario, NY) were used as standards for GPC analysis. To confirm the drug was 
encapsulated in the micelles, GPC peak fractions were collected and dried by 
Speed-Vap. The dried micelle fractions were re-dissolved in methanol and then 
analyzed by reversed-phase HPLC. 
92 
 
The drug loading efficiency (DL %) and encapsulation efficiency (EE %) of 
ridaforolimus in DSPE-PEG2000 micelles were calculated according to the 
following equations: 
DL % =
weight of the drug in micelle
weight of the  polymer and drug
 × 100 % (1) 
EE % =  
weight of the drug in micelle
weight of the feed drug
 × 100 % (2) 
The in vitro release of the drug from DSPE-PEG2000 micelles into PBS (pH 7.4) 
was done by a dialysis method. Dialysis was carried out at 37 °C under sink 
condition using a 10-kDa MWCO dialysis tubing (SnakeSkin®, Thermo Scientific 
Inc., Rockford, IL). The initial volume of drug-loaded micelles in the dialysis 
tubing was 2 mL and the sink solution was 4 L. The PBS was changed several 
times per day to maintain sink conditions. After pre-determined time intervals, 
samples were withdrawn from the dialysis bag and analyzed by a reversed phase 
HPLC column (TSK-GEL ® ODS-100Z, Tosoh Bioscience) at 50 °C with UV 
detection at 290 nm. 
3.2.4 Cellular uptake of DSPE-PEG2000 micelles 
Prostate cancer cell line, DU145, was maintained in RPMI-1640 medium and 
head and neck cancer cell line, MDA-1986, was kept in Dulbecco Modified Eagle 
Medium (DMEM). Both medium were supplemented with 10 % fetal bovine 
serum (Hyclone Laboratory Inc., Logan, Utah). Cells were plated in 96-well flat-
bottomed plates at a concentration of 10,000 cells per 90 μL of growth medium. 
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After the cells attached to the surface, ridaforolimus dissolved in DMSO or 
encapsulated in DSPE-PEG2000 micelles was added at concentrations of 0, 5, 10, 
25, 50 µM. After a 6-h treatment, the cell culture medium was removed and 
analyzed for extracellular drug content by HPLC. 
3.2.5 LC/MS analysis of Ridaforolimus 
The LC/MS system was a Shimadzu LCMS-2010 EV liquid chromatograph 
mass spectrometer system (Kyoto, Japan) connected to the LC portion 
consisting of two LC-10AD pumps, a SIL-10AD VP auto injector, a SPD-10A VP 
UV detector, and a SCL-10A VP system controller was used. Data analysis was 
accomplished using Shimadzu LCMS Solutions Version 3 software. A 
Phenomenex® Luna C18 (2) analytical column (250 x 4.6 mm; 5 µm) was used 
with a mobile phase of methanol, water, and formic acid (90:10:0.1, v/v/v) 
modified with 2 mM ammonium acetate at a flow rate of 0.5 mL/min. 
Pterostilbene was used as an internal standard. Positive selective ion monitoring 
(SIM) was used for detection of ridaforolimus at m/z 1012.60 (sodium adduct) 
and pterostilbene at m/z 257. Sodium adduct formation of other 
immunosuppressants have been reported (13, 14).  This LC/MS method was 
linear over 0.05 - 10 μg/mL concentration range with a lower limit of quantitation 
(LLOQ) of 0.05 μg/mL. Interday precision and accuracy for the method were 
within the acceptance criteria of < 15%. 
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3.2.6 Surgical Procedures 
Male Sprague-Dawley rats (~ 250 g) were obtained from Simonsen Labs 
(Gilroy, CA, USA) and given food (Purina Rat Chow 5001) and water ad libitum in 
our animal facility for at least 3 days before use. Rats were housed in 
temperature-controlled rooms with a 12 h light/dark cycle. The day before the 
pharmacokinetic experiment, the right jugular veins of the rats were catheterized 
with sterile silastic cannula (Dow Corning, Midland, MI, USA) under isoflurane 
anesthesia. After cannulation, the Intramedic PE-50 polyethylene tubing (Becton, 
Dickinson and Company, Franklin Lakes, NJ, USA) connected to the cannula 
was exteriorized through the dorsal skin. The cannula was flushed with 0.9 % 
saline. The animals were transferred to metabolic cages and fasted overnight. 
Animal use protocols were approved by The Institutional Animal Care and Use 
Committee at Washington State University. 
3.2.7 Pharmacokinetic study 
On the days of the experiment, animals were intravenously administered a 
single bolus injection of either ridaforolimus in ethanol/PEG 400 (10 mg/kg, n = 7) 
or the ridaforolimus in DSPE-PEG2000 (10 mg/kg, n = 7). These dosages were 
based on dose varying studies previously conducted in our laboratory with the 
structurally similar compound, rapamycin, and is in accordance with animal 
studies of ridaforolimus (5, 6). 
After dosing, serial blood samples (~0.30 mL) were collected from the cannula 
at 0, 1 min, and 30 min, then 1, 2, 4, 6, 12, 24, and 48 h after intravenous 
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administration, and the cannula flushed with 0.9 % saline. After dosing and after 
each serial blood sampling, blinded observers were present to record any visible 
behavior, bleeding, or change in overall appearance of the animal as signs of 
acute tolerability. Each blood sample was collected and following centrifugation, 
the serum was collected and stored at –70 C until analyzed.  
3.2.8 Sample preparation 
To extract ridaforolimus from serum samples, an ethyl acetate extraction was 
used. To 100 µL of serum sample, 10 µL of IS (100 µg/mL), 200 µL HPLC-grade 
water, and 1 mL of ethyl acetate were added. Samples were vortexed for 30 s, 
centrifuged at 5000 rpm for 5 min, and the organic phase transferred to a new 
sample tube and dried under a stream of nitrogen gas. Dried samples were 
reconstituted with 100 µL of mobile phase and 10 µL injected into the LC/MS 
system. 
3.2.9 Pharmacokinetic analysis 
    Pharmacokinetic analysis was completed using data from individual rats for 
which the mean and standard error of the mean (SEM) were calculated for each 
group except for Tmax which was represented as median and range. 
Pharmacokinetic parameters were estimated through noncompartmental analysis 
by the methods of Gibaldi et al. (15). The apparent terminal elimination rate 
constant (ke) was estimated from the slope of the log–linear phase of declining 
serum concentration vs. time plot. The half-life (t1/2) was calculated using the 
following equation: t1/2 = 0.693/ke. The area under the concentration time curve 
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(AUC0-Clast) was calculated using the linear/logarithmic trapezoidal method. 
Summation of AUC0–Clast and the concentration at the last measured point divided 
by ke yielded AUC0–∞. Mean residence time (MRT) was calculated by dividing 
AUMC0-∞ by AUC0-∞, clearance (Cl) by dividing dose by AUC0-∞, and volume of 
distribution (Vss) by multiplying MRT by Cl. 
3.2.10 Statistical analysis 
    Quantification was based on calibration curves constructed using peak area 
ratio (PAR) of ridaforolimus to internal standard, against ridaforolimus 
concentrations using unweighted least squares linear regression. 
Pharmacokinetic analysis was performed using data from individual rats for 
which the mean and standard error of the mean (SEM) were calculated for each 
group. The data were analyzed for statistical significance in Microsoft Excel® 
using student’s t-test with a value of p < 0.05 being considered statistically 
significant. 
3.3 Results and Discussion 
3.3.1 Formulation of ridaforolimus in DSPE-PEG2000 micelles 
The formation of drug loaded DSPE-PEG2000 was confirmed by GPC study 
(Fig. 2A). Loading of ridaforolimus into DSPE-PEG2000 micelles greatly improved 
the aqueous solubility of ridaforolimus by approximately 40 times from 200 μg/mL 
to 8.9 mg/mL (6). The diameters of the drug-loaded micelles as determined by 
DLS were 33 ± 15 nm (Fig. 2B). This size range has been shown appropriate for 
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extended circulation time in vivo and accumulation within the tumor through the 
EPR effect (9). 
3.3.2 Micelle characterization 
Micelles appeared as a distinct peak on SEC, with a retention time of 6.966 
min for the DSPE-PEG2000 micelles (873,000 Da using PEG standards) (Fig. 2A). 
The micelle fractions were collected and assayed for drug content by HPLC with 
UV detection. Ridaforolimus was found in the micelle GPC peak, and the HPLC 
retention time was identical to the standard with no additional peaks. The drug 
loading efficiency (DL %) for 10 % (w/w) drug loaded micelles was 7.194 ± 0.143 
% and the encapsulation efficiency (EE %) was 77.519 ± 1.658%. 
The in vitro release profiles of free drug and micelle formulation of 
ridaforolimus were investigated at simulated in vivo conditions using a PBS bath 
at pH 7.4 and 37 °C (Fig. 3). The in vitro t50% was improved from less than 20 min 
to 1.5 d and t90% was increased from 1 h to 6.5 d (Fig. 3). 
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Fig. 2: (A) GPC chromatography of ridaforolimus loaded DSPE-PEG2000 micelles in 
water mobile phase at 0.8 mL/min with ELSD detection. (B) Size distribution of 
ridaforolimus loaded DSPE-PEG2000 micelles indicating an average diameter of 33 nm. 
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Fig. 3: Release profile of ridaforolimus in PEG-DSPE2000 micelles () 
compared to free drug in PBS () (mean ± SD) (n=3). 
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3.3.3 Micelle formulation effects on cellular uptake of the drug 
    The DU145 and MDA-1986 cells were treated with naked ridaforolimus 
and ridaforolimus loaded DSPE-PEG2000 micelles. After a 6-h treatment, the 
drug uptaken by the cells was quantified by HPLC (Fig. 4). Micelle 
formulation significantly improved the cellular uptake at all concentrations in 
both DU145 and MDA-1986 cells. In addition, DMSO was not required to 
solubilize ridaforolimus in the micelle formulation. 
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Fig. 4: The micelle formulation improved ridaforolimus uptake by DU145 cells 
(A) and MDA-1986 cells (B) (mean ± SD). (*: p < 0.01 between formulations 
the same concentration) 
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3.3.4 Pharmacokinetic evaluation of a DSPE-PEG2000 formulation of 
Ridaforolimus 
Tolerability and the pharmacokinetic disposition of two ridaforolimus 
formulations were assessed. No observable differences were seen in the 
tolerability of the ethanol/PEG400 formulation and DSPE-PEG2000 micelle 
formulation among blinded observers. No tolerability differences were 
expected as the appearance of the toxicities associated with mTOR 
inhibitors are most often delayed (e.g. mucositis). 
Pharmacokinetic differences between the micellar and ethanol/PEG 400 
formulations of ridaforolimus following intravenous administration are 
illustrated in Fig. 5. Ridaforolimus in the control formulation of 
ethanol/PEG400 exhibited a rapid distribution and elimination from the body 
where concentrations fell below detectable limits after 4 h post-dose. 
Solubilization of ridaforolimus in DSPE-PEG2000 micelles provided a slightly 
more sustained release and quantifiable presence of ridaforolimus in serum 
up to 12 h. Non-compartmental analysis of the pharmacokinetic parameters 
of these formulations are reported in Table 1. The micelle nanocarrier 
formulation increased elimination half-life (t1/2) by 1.7-fold and decreased 
the clearance by 0.6 fold. This may indicate that the micelle formulation 
increases the serum circulation time of ridaforolimus in vivo. The micelle 
formulation also increased the AUC by 3.7-fold and decreased the Vss by 
1.8-fold, but these were not statistically significant (p < 0.05). 
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Table 1: Pharmacokinetics of ridaforolimus after IV administration of control 
ridaforolimus in ethanol/PEG400 and ridaforolimus in DSPE-PEG2000 micelles. The 
intravenous dose for all the formulations was 10 mg/kg to rats (mean ± SEM, n = 7 
per group). *Significantly different from formulation in ethanol/PEG 400 (p < 0.05). 
PK Parameters 
Ridaforolimus in 
ethanol/PEG400 (mean ± SEM) 
Ridaforolimus in DSPE-
PEG2000 micelles 
(mean ± SEM) 
AUC 0→∞ (h×µg/ml) 1.40 ± 0.23 5.16 ± 2.13 
Vss (l/kg) 10.82 ± 2.10 6.05 ± 2.10 
Cltotal (l/h/kg) 8.31 ± 1.58 3.45 ± 0.79* 
t1/2 (h) 1.20 ± 0.11 3.18 ± 0.64* 
MRT (h) 1.34 ± 0.15 1.57 ± 0.51 
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Fig. 5: Concentration-time profile in serum of ridaforolimus after intravenous 
administration of control ridaforolimus formulation in ethanol/PEG400 and ridaforolimus in 
DSPE-PEG2000 micelles. The dose for all the formulations was 10 mg/kg to rats (mean ± 
SEM, n = 7 per group). 
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    Previous attempts to solubilize highly lipophilic compounds with polymeric 
micelles have showed dramatic alteration in the pharmacokinetics and 
biodistribution of these compounds. For instance, encapsulation of paclitaxel 
prodrugs into PEG-b-PCL micelles increased the AUC0-∞ of the prodrug 54-
fold in comparison to control while improving tolerability and altering 
paclitaxel’s biodistribution (11). For unclear reasons, solubilization of 
ridaforolimus in DSPE-PEG2000 micelles did not dramatically increase the 
residence time or the overall systemic exposure of ridaforolimus. This may be 
indicative of a lack of in vivo stability or an inability to evade the mononuclear 
phagocyte system. DSPE-PEG is well established to have detergent-like 
properties that may disrupt the balance of hydrophobicity and hydrophilicity of 
the nanocarrier. This is most well known in liposomes where DSPE-PEG is a 
common PEGylate choice yet can also be responsible for disrupting the lipid 
membrane (10). 
    No other reports of solubilization of ridaforolimus in micelles or other forms 
of nanocarriers are available in the biomedical literature. However, there are 
reports of the encapsulation of rapamycin, the parent drug of ridaforolimus, 
using PEG-b-PCL and DSPE-PEG2000 micelles (5, 11, 12).  The 
pharmacokinetics of rapamycin in these micelles has only been evaluated 
with the PEG-b-PCL formulation. The PEG-b-PCL greatly improved the 
tolerability of rapamycin with decreased distribution of rapamycin into brain 
tissue (5). The formulation, however, had no significant effect of the 
pharmacokinetic disposition of rapamycin with only a longer t1/2 being 
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significant (5). These results appear to be in accordance with the results 
found in this study. 
    To our knowledge, this is the first report of the pharmacokinetics of 
ridaforolimus in rats. The results reported herein vary greatly from those 
reported in clinical Phase I trials of ridaforolimus in humans suggesting 
species dependent pharmacokinetics. Within these human trials, a much long 
half-life of 45-52 h is reported (3).  Possible differences may stem from limits 
reached analytically as the LC/MS method reported here could detect 
ridaforolimus only to 50 ng/mL while LC/MS/MS used in clinical studies 
allowed detection to 0.5 ng/mL (3). This may have prevented accurate 
estimation of the terminal phase of elimination. Additionally, data reported 
within were collected from rat serum rather than whole blood. The 
concentrations of ridaforolimus in the serum component may have simply 
been too low for proper analytical quantitation. 
    It was hypothesized at the beginning of this study that encapsulation within 
DSPE-PEG2000 micelles would greatly alter the pharmacokinetic parameters 
of ridaforolimus. A decrease in volume of distribution was anticipated due to 
an expected decrease in partitioning of ridaforolimus to the red blood cell 
compartment. Limiting red blood cell partitioning could have theoretically 
limited saturation of the substantial amount of FKBP-12 binding protein within 
erythrocytes. This saturation has been suggested as a possible reason for 
the lack of dose proportionality with ridaforolimus and other rapamycin 
analogs. Taken together, it can be speculated that it may have been possible 
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to improve the dose proportionality of ridaforolimus by solubilizing in a 
nanocarrier system. However, no significant changes in volume of distribution 
were seen, but there were trends for a decrease in volume. 
These are the first of results in the literature describing the 
pharmacokinetics of ridaforolimus in rats as well as the first results presenting 
its formulation via nanocarriers. Other work in our laboratory continues to 
explore solubilizing lipophilic drugs in nanocarriers and the effects these 
formulations have on disposition of these drugs. 
3.4 Conclusions  
The DSPE-PEG2000 micellar formulation dramatically improved the solubility of 
ridaforolimus and provided optimum sizing of the micelle particles. Upon intravenous 
administration of ridaforolimus loaded DSPE-PEG2000 micelles to rats, alterations in 
the pharmacokinetics of ridaforolimus could be detected. This included a significant 
increase in half life and decrease in clearance, and non-significant changes in AUC 
and volume of distribution. These results suggest that the micelle formulation may 
increase the retention of drug, but the micelle formulation may have limited stability 
in vivo. Since the micelle formulation significantly enhances the drug’s aqueous 
solubility and eliminates harmful excipients, the toxicity profile may be improved. The 
toxicity and efficacy in xenografts will be reported in a future study. 
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 Pharmaceutical Characterization, Disposition and Efficacy of Hyaluronic acid-
Rapamycin Conjugates 
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4.1 Introduction 
CD44 is a cell surface molecule involved in proliferation, differentiation and 
migration, etc (1). The CD44 receptor is one of the most widely accepted cell surface 
markers of variety types of cancer cells, such as breast cancer cell lines MCF-7, 
MDA-MB-468 and MDA-MB-231 (2); prostate cancer cell lines PC-3 and TSU-Pr1 
(3); and head and neck cancer Gun-1. The expression of specific CD44 isoforms is 
also associated with various cancer biomarkers and tumor subtypes (4). The ligands 
of CD44 include hyaluronic acid (HA), osteopontin, collagens and matrix 
metalloproteinases. CD44 receptor mediates cell-cell and cell-matrix interactions 
through its affinity with HA and the adhesion with HA molecule plays an important 
role in tumor growth and progression. Therefore, the interaction of CD44 and HA 
was reported as a potential target for cancer therapy (5, 6).  
The usage of HA as a polymer for drug delivery could provide specific cancer 
targeting and the benefits associated with polymer-drug conjugates. The polymer-
drug conjugates are designed to increase therapeutic index by drug specific 
targeting of disease, tissues, reducing systemic drug exposure (7, 8), and increased 
plasma circulation time. Polymer-drug conjugate based anticancer agents have 
entered routine clinical use, such as Cimzia® (certolizumab-polyethylene glycol40k), 
Xyotax® (paclitaxel-poly-L-glutamic acid) and Macugen® (polyethylene glycol-
conjugated RNA aptamer) (9-11). The polymer-drug conjugates can be bio-activated 
to provide their own therapeutic benefits, and they also can improve release kinetics 
of the drug and prevent carrier accumulation in the body (12). Moreover, the polymer 
based drug delivery platform has demonstrated prolonged in vivo half-life, is less 
prone to enzyme degradation with less immunogenicity compared to the 
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conventional chemotherapy (13-15). It also provides an effective and promising way 
for neoplastic treatment due to the changing of cellular uptake mechanisms, 
pharmacokinetic disposition and ultimately targeting of the drug (16). 
Rapamycin is a selective inhibitor of mammalian target of rapamycin (mTOR) and 
blocks the subsequent activation of p70 S6 kinase (17). The mTOR pathway 
regulates a variety of cellular signals and development processes, including 
mitogenic growth factors, hormones, nutrients, cellular energy levels and stress 
conditions (18). It is frequently activated in certain human cancers, such as breast 
cancer (19) and gastric cancer (20). The mTOR pathway is also widely involved in 
both apoptotic and autophagic pathways during oxidative stress (21, 22). Therefore, 
inhibiting the mTOR pathway is extensively considered as an effective approach for 
targeted cancer therapy (23). A 2-year clinical trial of rapamycin on renal 
angiomyolipoma in tuberous sclerosis showed that mTOR inhibitors are relatively 
safe, efficacious and less aggressive (24). However, systemic toxicity was observed 
after administration of rapamycin, inducing fevers, anemia and capillary leak 
syndrome (25). To lower the systemic toxicities, localized delivery of rapamycin using 
biodegradable bead (35:65 ratio of caprolactone and glycolide) for the treatment of 
malignant glioma was reported. In an animal study it was demonstrated that a 
significantly longer survival with targeted rapamycin therapy was possible compared 
to the free drug and the placebo groups (26).  
In this study, HA-rapamycin conjugates prepared with different linkers were 
synthesized. Sustained and controlled release of the drug was achieved. Both 
chemical and physical properties of the polymer-drug conjugate were fully 
characterized. In vitro studies were performed to examine CD44-mediated cancer 
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cell uptake. Efficacy of the drug conjugate was evaluated in BALB/c mice and 
pharmacokinetics studies were completed in Sprague-Dawley rats. 
4.2 Materials and Methods 
4.2.1 Materials 
    Hyaluronic acid (35 kDa) and rapamycin were purchased from Lifecore 
Biomedical, Inc. (Chaska, MN) and LC Laboratories (Woburn, MA), respectively. 
Fmoc-3-amino-4-methoxy-benzoic acid was purchased from AnaSpec, Inc. 
(Fremont, CA). Other materials and solvents, of their highest grade, were 
purchased from Fisher Scientific (Lenexa, KS) or Sigma Aldrich (St. Louis, MO), 
and they were used as received unless stated otherwise. NMR spectra were 
collected with a 400-MHa Bruker and the mass spectra were obtained by 
electrospray ionization mass spectrometry (ESI-MS).  
4.2.2 Synthesis of rapamycin 42-hemisuccinate 
    The synthetic scheme is shown in Fig. 1A. A mixture of rapamycin (0.20 g, 
0.22 mmol), succinic anhydride (0.10 g, 1.0 mmol) and Novozym SP 435 (0.45 g) 
in toluene (10 mL) was stirred at 45 oC under argon for 40 h. The enzyme was 
filtered off and washed with toluene, and the combined organic phases were 
concentrated under reduced pressure. The residue was purified by silica gel 
column chromatography and eluted with EtOAc-hexane (1:4) to furnish the title 
compound as a white solid (0.2 g, 90%) (27).  
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Fig. 1: Synthesis of Hyaluronic Acid (HA)-Temsirolimus (A) and Hyaluronic Acid-
Rapamycin-42-(3’-amino-4’-methoxy)benzoate (HA-L-Rapa) (B). 
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4.2.3 Synthesis of Hyaluronic Acid (HA)-Temsirolimus 
    The 42-hemisuccinated rapamycin (0.150 g, 0.15 mmol) was dissolved in 4 mL 
of dimethyl sulfoxide (DMSO), and 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDC·HCl) (0.057 g, 0.30 mmol) and 1-
hydrocybenzotriazole hydrate (HOBt·H2O) (0.046 g, 0.30 mmol) were added to 
the solution. After 20 min, this solution was added drop wise to HA-adipic acid 
dihydrazide (ADH) (0.120 g, 22 % ADH) in 10 mL of double distilled water 
(ddH2O) cooled on ice. HA-ADH was synthesized as previously described (27). 
After the addition, the mixture was stirred at ambient temperature (ca. 20°C) 
overnight. Then, the solution was poured into 100 mL of 95 % ethanol (EtOH), 
and the white precipitate was collected by centrifugation. This procedure was 
repeated another two times. The collected solid was dried under vacuum 
overnight and 0.085 g of the product was obtained (yield: 31.48 %). The loading 
degree of rapamycin on the conjugate was verified by 1H-NMR. 
4.2.4 Synthesis of Hyaluronic Acid-Rapamycin-42-(3’-amino-4’-methoxy)benzoate 
(HA-L-Rapamycin) 
The synthetic scheme of HA-L-rapamycin is shown in Fig. 1B. 
Five milliliters of oxalyl chloride in dry methylene chloride (2.0 M in DCM) was 
added to 150 mg of Fmoc-3-amino-4-methoxy-benzoic acid along with one drop 
of dry dimethylformamide (DMF) as a catalyst. The mixture was stirred at 
ambient temperature (ca. 22 °C) under dry argon for 2 h. The white suspension 
turned into a light yellow, clear solution as the reaction neared completion. The 
organic solvent was removed under reduced pressure.   
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Compound 1 was suspended in 5 mL of dry DCM and 100 mg of rapamycin 
and 200 mg of NaHCO3 were added to the solution. The mixture was stirred at 
ambient temperature for 2 h under dry argon and protected from light. The 
suspension was filtered, and the filtrate was washed with bicarbonate water and 
brine. The organic solvent was dried with Na2SO4 and then removed under 
reduced pressure.  
Compound 2 was suspended in 20 % (v/v) piperidine in DMF. The solution was 
stirred at ambient temperature for 1 h. The organic solvent was removed under 
reduced pressure and the pale yellow solid was washed several times with 
ddH2O.  
O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate 
(HATU) (100 mg, 0.26 mmol) in 1 mL of DMF and N,N-Diisopropylethylamine 
(DIPEA) (47 µL, 0.27 mmol) were added to 100 mg HA in 5 mL of ddH2O. After 
30 min, rapamycin-42-(3’-amino-4’-methoxy) benzoate in 5 mL of DMF was 
added. The mixture was stirred at ambient temperature overnight. Then, the 
organic solvent was removed by dialysis (10k MWCO snake skin pleated dialysis 
tubing, Thermo Scientific, Rockford, IL) against ddH2O. The unbound drug 
produced a light yellow precipitate that was removed by centrifugation. The drug 
conjugate was further purified by tangential flow filtration (TFF) using a MicroKros 
mPEG filter (3.5k MWCO, Spectrum Labs, Rancho Dominguez, CA).  Briefly, the 
mPES MicroKrosMix® Hollow Fiber Filter module was flushed by ddH2O under a 
pressure of 10 psi provided by a Manostat Varistaltic dispenser and pump. After 
the filter membrane was fully hydrated and washed with ddH2O, the filter module 
was fed with the HA-L-Rapa solution maintaining a pressure of less than 10 psi, 
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and the drug conjugate solution was concentrated by maintaining the pump 
pressure at less than 20 psi. The rapamycin loading degree on HA was 
determined by 1H-NMR. 
4.2.5 In Vitro Drug Release Study 
    The in vitro release of the rapamycin from HA-drug conjugates into PBS or 
PBS supplemented with 10 % fetal bovine serum (FBS) at 37 ⁰C was monitored 
by a dialysis method using a SnakeSkin® pleated dialysis tubing (3,500 MWCO) 
(28). To prevent bacteria growth, 0.05 % sodium azide was added to the serum 
release medium, and the medium was changed several times a day to maintain 
sink conditions. After the predetermined time intervals, samples were withdrawn 
from the dialysis tubing and analyzed using a Spectra MaxM2 microplate 
spectrophotometer with UV detection of rapamycin at 260 nm. 
4.2.6 HA-Rapamycin Conjugate Characterization 
4.2.6.1 Particle Size 
     HA and HA-L-Rapa with different loading degrees were dissolved in PBS at 
the concentration of 2.5 mg/mL. The particle sizes were measured with a 
ZetaPALS (Brookhaven Instruments Corp.) using the intensity weighted 
Gaussian distribution.  
4.2.6.2 Zeta Potential  
HA and HA-L-Rapa with different loading degree were dissolved in 10 mM KCl 
at the concentration of 2.5 mg/mL. Zeta potentials were measured using 
ZetaPALS. Zeta potential was calculated from the mobility of the system fitted 
into the Smoluchowski model (29). 
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4.2.6.3 Turbidity  
    One hundred microliter samples at the concentration of 2.5 mg/mL were 
placed in a 96-well flat-bottomed plate (Greiner Bio-One UV Star). The turbidities 
in the wells were measured as absorbance at 350 nm using a Spectra MaxM2 
microplate spectrophotometer and determined in triplicate. 
4.2.7 Thermal Analysis  
4.2.7.1 Differential scanning calorimetry (DSC)  
    HA-L-Rapa with different loading degrees and HA35k polymer, as received, 
were studied using a Q100 Universal V4.3A DSC (TA Instruments, New Castle, 
Delaware). The samples were sealed in a standard aluminum pan and heated 
from 40 to 300 ⁰C at a scan rate of 10 ⁰C/min.  
4.2.7.2 Thermo gravimetric analysis (TGA)  
    TGA was performed on a Q50 thermogravimetric analyzer from TA 
Instruments. Samples were loaded on a platinum sample pan and heated from 
25 to 500 ⁰C with a heating rate of 10 ⁰C/min. Data were analyzed using 
Universal Analysis 2000 (version 4.3A) software (TA Instrument). 
4.2.8 Flow Cytometry Analysis 
    The expression of CD44 receptor on the surface of breast cancer cells, MDA-
MB-468 and 4T1.2neu, was examined by flow cytometry analysis. PE mouse 
anti-human CD44 (BD Pharmingen, San Jose, CA) was used to stain MDA-MB-
468 cells, and PE rat anti-mouse CD44 (Pgp-1-R-PE, Southern Biothech, 
Birmingham, AL) was used with murine 4T1.2neu cells. PE mouse IgGI isotope 
control (BD Pharmingen, San Jose, CA) was used as a control. Anti-human 
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CD44 antibody (H-CAM, Thermo Scientific, Rockford, IL) was used in receptor 
blocking assays.  
4.2.9 Cytotoxicity Assay 
    Breast cancer MDA-MB-468 cells were maintained in Dulbecco’s modified 
eagle medium supplemented with 10 % fetal bovine serum (Hyclone Laboratory 
Inc., Logan, Utah). Cells were plated in white 96-well flat-bottomed plates at the 
concentration of 5,000 cells/well in 90 µL of growth medium. After 12 h, 
rapamycin or HA-L-Rapa in Hanks’ solution were added at different 
concentrations. Hanks’ solution and 10 % trichloroacetic acid (TCA) were used 
as negative and positive control, respectively. The medium was refreshed 8 h 
after treatment. After 72 h post-treatment, resazurin blue (5 µM) was added and 
the resorufin product was measured with a fluorophotometer using an excitation 
wavelength of 550 nm and an emission wavelength of 590 nm.   
4.2.10 Cellular Uptake Study 
Breast cancer cells, MDA-MB-468, were seeded in a 12-well plate at the 
concentration of 50,000 cells/well in 1 mL of growth medium. After 12 h 
incubation, 10 µL of human anti-CD44 antibody was added to each well. After 1 
h, 10 µM of rapamycin or HA-L-Rapa conjugate were added to the cells. The 
supernatant was then analyzed by HPLC with a reverse phase column (TSK-
GEL® ODS-100Z, Tosoh Bioscience) at 50℃ and UV detection at 278 nm for 
rapamycin. The chromatography conditions were a mobile phase A of 0.002 % 
(v/v) TFA in ddH2O and B of 0.002 % (v/v) TFA in acetonitrile (ACN) at a flow rate 
of 1 mL/min. The gradient program was i) 5 min with 10 % B; ii) a linear gradient 
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from 10 % to 90 % B over 5 min; iii) 8 min with 90 % B; and iv) 7 min with 10 % 
B. The retention time of rapamycin was 16.05 min. 
4.2.11 Pharmacokinetics Study 
Female Sprague-Dawley rats (350 - 450 g, Charles Rivers) were administered 
rapamycin (1 mg/mL in formulation buffer) by intraperitoneal (i.p.) injection or HA-
L-Rapa (10 mg/kg equivalent rapamycin; n = 3 for each group) by subcutaneous 
(s.c) injection under isoflurane anesthesia. Whole blood was withdrawn (100 µL) 
from the tail vein at 0 min, 5 min, 30 min, 1 h, 2 h, 4 h, 6 h, 12 h, 24 h and 48 h 
after dosing and placed in heparinized tubes (BD Vacutainer® Lithium Heparin 
37 USP unit, BD Franklin Lakes, NJ). The whole blood was centrifuged at 15,000 
× g for 10 min, and the plasma was frozen at -80°C until analyzed. The animal 
use statement was approved by the University of Kansas Institutional Animal 
Care and Use Committee. 
Plasma samples and standard curves were prepared using a procedure 
reported previously (30). Briefly, in a microcentrifuge tube, 125 µL of ddH2O, 125 
µL of 0.1 M zinc sulfate and 250 µL of methanol were added to 100 µL of plasma. 
Then, the tubes were vortexed and centrifuged for 5 min. The colorless 
supernatant was injected into the LC/MS system. The analyses were performed 
on an AB Sciex 3200 Q TRAP LC/MS/MS system (Framingham, MA). In the 
positive-ion mode, the monitored single plot transitions (m/z) was 936  937. 
The separation was carried on Shimadzu SIC-20 UFLC (Shimadzu Scientific 
Instrument, Overland Park, KS) with an Ascentis® C18 5 cm × 2.1 mm, 3 µm 
column (Seattle, WA) maintained at 40 °C. The mobile phases were: (A) 
ddH2O/Acetonitrile/Formic acid 95/5/0.1 (v/v/v) and (B) ddH2O/Acetonitrile/Formic 
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acid 5/95/0.1 (v/v/v). The gradient program was: i) a linear gradient from 50 % to 
90 % B over 3 min; ii) 3 min with 90 % B; iii) 4 min with 50 % B. The rapamycin 
retention time was 3.96 min. 
4.2.12 Animal Survival Study and Tissue Distribution 
The murine breast cancer 4T1.2neu cell line was used to establish the 
synergetic orthotropic tumor model in immunocompetent mice. Female BALB/c 
mice (20 - 25 g, Charles Rivers) under isoflurane anesthesia were inoculated in 
the right mammary gland with 1 × 106 cells suspended in PBS. Treatment started 
when the tumor size reached 50 mm3. Free rapamycin was dissolved in 
anhydrous ethanol and reconstituted in formulation buffer before use. The 
formulation buffer of free rapamycin consisted of 5 % polyethylene glycol 400 
and 5 % Tween 80 in Hanks’ balance salt solution. HA-L-Rapa was dissolved in 
Hanks’ solution. Mice received 10 mg/kg equivalent rapamycin once per week for 
3 weeks by i.p. injection (free rapamycin) or s.c injection (HA-L-Rapa). Control 
animals were injected with Hanks’ solution. Animals were sacrificed when tumors 
grow larger than 1000 mm3 or if the tumors ulcerated in accordance with the 
approved animal use protocol. 
Drug tissue distribution was determined in female BALB/c mice (n = 5). Tissue 
samples (50 mg) in 500 µL PBS were homogenized using a Tissue Tearor 
(BioSpec Products, Inc., Bartlvesville, OK). The homogenized tissue was mixed 
with 250 µL ZnSO4 and 500 µL methanol. The mixture solution was centrifuged 
and the supernatant was analyzed by LC/MS. 
In the tissue distribution study, BLAB/c mice were administered the drugs 12 h 
before being euthanized. Major organs (liver, kidneys, hear, spleen, lungs, brain, 
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muscle), tumor and lymph nodes were excised and lightly washed with PBS. The 
organs were stored at -80°C until analyzed by LC/MS.  
4.2.13 Statistical Analysis 
GraphPad Prism 5 software was used for statistical analysis. A t-test was used 
for statistical analysis of comparing two means. The Mantel-Cox test was used 
for comparison of Kaplan-Meyer analysis. In all comparisons, statistical 
significance was set at p ≤ 0.05.  
4.3 Results  
4.3.1 Polymer Drug Conjugates Synthesis 
4.3.1.1 Hyaluronic Acid (HA)-Temsirolimus  
    Rapamycin 42-hemisuccinate was synthesized according to previous protocols 
(27). High resolution mass spectrometry (ESI) Calcd for C55H83NO16Na (M + 
Na)+: 1036.5610; Found: 1036.5623, which was consistent with the reported 
data. 
    1H-NMR (D2O, 400 MHz): δ = 6.79 (m, 1H), 6.18 (m, 1H), 5.95 (m, 1H), 5.50 
(m, 1H), 5.21 (m, 1H ), 4.47 (broad doublet, 1H on HA), 4.37 (broad doublet, 1H 
on HA), 4.38-4.45 (broad multiplicity, 8H on HA), 3.43-3.39 (broad doublet, 2H on 
HA), 3.26 (s, 3H), 3.22 (s, 3H), 2.68 (m, 2H), 2.61 (m, 2H), 1.92 (bs), 1.82 (m, 
3H), 1.45 (m, 1H), 1.08 (t, 3H), 0.98 (t, 3H). 
4.3.1.2 Rapamycin-42-(Fmoc-3’-amino-4’-methoxy) benzoate  
1H-NMR (MeOH-d4, 400 MHz): δ = 8.47 (s, 1H), 7.80 (d, J = 7.6 Hz, 2H), 7.77 
(d, J = 8.5 Hz, 1H), 7.67 (d, J = 6.5 Hz, 2H), 7.40 (t, J = 7.3 Hz, 2H), 7.40 (t, J = 
7.4 Hz, 2H), 7.01 (d, J = 8.4 Hz, 1H), 6.86-6.71 (m, 1H), 6.65-6.49 (m, 2H), 6.44-
6.10 (m, 5H), 5.78-5.66 (m, 1H), 5.57-5.43 (m, 2H), 5.37-5.15 (m, 3H), 4.45 (d, J 
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= 6.9 Hz, 2H), 4.30 (d, J = 6.8 Hz, 1H), 4.27-4.25 (m, 1H), 4.21-4.04 (m, 2H), 
3.99-3.93 (m, 2H), 3.92 (s, 3H), 3.66-3.62 (m, 1H), 3.44-3.39 (m, 3H), 3.34 (s, 
3H), 3.33 (s, 3H), 3.32 (s, 3H), 2.99-2.89 (m, 2H), 2.84-2.56 (m, 1H), 2.37-2.21 
(m, 3H), 2.14-1.98 (m, 3H), 1.96-1.60 (m, 13H), 1.54-1.21 (m, 6H), 1.19-0.63 (m, 
25H). HRMS (ESI) Calcd for C74H96N2O17Na (M + Na)
+: 1307.6607; Found: 
1037.6650. 
4.3.1.3 Hyaluronic Acid-Rapamycin-42-(3’-amino-4’methoxy) benzoate  
    1H-NMR (D2O, 400 MHz): δ = 7.65 (d, J = 7.6 Hz, 1H), 7.47 (t, J = 7.5 Hz, 1H), 
7.39 (td, J = 7.5, 1.1 Hz, 1H), 6.41-6.35 (m, 1H), 6.20-6.14 (m, 1H), 5.95-5.86 (m, 
1H), 5.60-5.40 (m, 2H), 5.15-5.09 (m, 1H ), 4.47-4.39 (broad doublet, 2H on HA), 
4.39 (broad doublet, J = 7.0, 1H on HA), 3.89-3.86 (m, 2H), 3.85-3.80 (m, 4H), 
3.78-3.54 (broad multiplicity, 8H on HA), 3.51-3.49 (broad doublet, 2H on HA), 
3.42 (broad peak, 2H), 3.26 (s, 3H), 3.22 (s, 3H), 3.13-3.03 (m, 6H), 2.92 (d, J = 
0.3 Hz, 3H ), 2.83-2.80 (m, 4H), 2.79-2.77 (m, 4H), 2.76(m, 6H ), 2.68 (m, 2H), 
2.61 (m, 2H), 1.92 (broad singlet, 3H), 1.72-1.65 (m, 3H), 1.61-1.55 (m, 3H), 
1.50-1.43 (m, 2H), 1.28-0.90 (m, 30H). 
    Rapamycin loading degree was calculated based on the ratio of 2H on HA (δ = 
4.47-4.39) and 1H on rapamycin (δ = 5.15-5.09). 
4.3.2 In Vitro Drug Release Study 
HA-Temsirolimus and HA-L-Rapa were dissolved in ddH2O at the 
concentration of 2.5 mg/mL. Free rapamycin was dissolved in ethanol and ddH2O 
mixture. The dialysis medium was PBS or PBS supplemented with 10 % FBS. 
The release profiles were fitted using first (1) or second (2) order kinetics with the 
following equations: 
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A = A0e
-kt              (1) 
1/A = 1/A0+kt       (2) 
The release half-lives of free rapamycin (PBS), HA-Temsirolimus (PBS), HA-L-
Rapa (PBS), HA-L-Rapa (serum) were 0.16 h, 4 h, 7 d and 1.5 d, respectively. 
The rate constants of release for free rapamycin (PBS), HA-Temsirolimus (PBS), 
HA-L-Rapa (PBS) and HA-L-Rapa (serum) were shown in Table 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
126 
 
Table 1: Calculated release constants of free rapamycin, HA-Rapa and HA-L-Rapa. 
 k (day-1) A error 
Free Rapamycin 
1st order fit 
-27.23 33.48 1700.33 
HA-Rapa 
1st order fit 
-0.1469 22.08 692.99 
HA-L-Rapa 
1st order fit 
-0.07105 26.36 1574.43 
HA-L-Rapa 
2nd order fit 
-0.01767 4.807 19829.83 
HA-L-Rapa (serum) 
1st order fit 
0.9999 2.37 × 10-6 32815.21 
HA-L-Rapa (serum) 
2nd order fit 
-0.00344 29.56 3520.77 
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4.3.3 Characterizations of HA Drug Conjugates 
4.3.3.1 Particle sizes and Zeta potentials  
The non-conjugated HA35k and HA-L-Rapa with different drug loading degrees 
were dissolved in PBS at the concentration of 2.5 mg/mL. Particle sizes were 
determined by dynamic light scattering (DLS) (Table 2). There was no significant 
size difference between drug conjugated and non-conjugated HA. However, the 
absolute value of zeta potential decreased with increasing the drug loading 
degree on the HA. The negative zeta potential is expected as each HA monomer 
has one carboxylic group (pKa ~4.5) and one HA35k has approximately 87 
repeating units that yield a strong negatively charged nanoparticle at pH 7.4. By 
conjugating with rapamycin, a large hydrophobic molecule, carboxylic groups on 
HA surface were partially esterified by conjugation and some adjacent negative 
charged carboxylic groups were shielded by the drug; therefore, the absolute 
zeta potential value was decreased. 
4.3.3.2 Turbidity  
The turbidity test is an objective method to evaluate the solubility of a 
compound to the solvent. The solubility of HA35k and HA-L-Rapa conjugates were 
studied in PBS or Hanks’ balanced salt solution. At the same concentration, HA-
L-Rapa was more turbid in PBS than Hanks’ solution, whereas there was no 
difference for the HA35k control group (Fig. 2). 
This indicated that Hanks’ solution is a better formulation buffer than PBS. 
Both PBS and Hanks’ solution are isotonic buffered saline solution. However, 
glucose is supplemented to Hanks’ solution. Sugar molecules could bind to the 
HA or rapamycin through hydrogen-bonding. The hydrophobic surface of the  
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Table 2: Particle sizes and zeta potentials of HA-L-Rapa with different rapamycin 
loading degrees (Mean ± SD). 
 Size (nm) Zeta Potential (mV) 
HA35k 10 ± 0.045 -77.36 ± 14.78 
HA-L-Rapa 1.14 % (w/w) 9.8 ± 0.124 -56.15 ± 8.18 
HA-L-Rapa 2.21 % (w/w) 9.4 ± 0.012 -44.40 ± 8.11 
HA-L-Rapa 4.78 % (w/w) 10.7 ± 0.014 -13.10 ± 3.96 
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Fig. 2: Turbidity study of HA-L-Rapa with different loading degree in PBS or Hanks’ 
solution (mean ± SD) (n = 3; *, p < 0.05). 
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polymer-drug conjugate might be masked by sugar molecules and the solubility 
of the polymer-drug conjugates can be improved. 
4.3.3.3 DSC  
    Thermally induced conformational transitions of rapamycin, HA35k and HA-L-
Rapa with different drug loading degree are shown in Fig. 3. The rapamycin 
showed two endothermic peaks at 187 °C and 200 °C. The free HA35k was 
characterized by a broad endothermic at 120 °C and an exothermic peak at 
240 °C. The first broad endothermic peak of HA at approximately 120 °C 
suggests a dehydration process. An exothermic peak at ca. 240 °C was 
attributed to the decomposition of the polymer. The free rapamycin was 
characterized by two endothermic peaks at 187 °C and 200 °C. The split peak 
indicated that there are two crystalline structures of pure rapamycin. However, 
the second exothermic characteristic peak of HA35k was not observed in HA-L-
Rapa conjugates’ DSC profiles. In addition, the two endothermic peaks of free 
rapamycin merged together and shifted to a higher temperature (210 °C).  
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Fig. 3: DSC profiles of free rapamycin, HA and different loading degree HA-L-Rapa. 
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    Both the characteristic decomposition DSC peaks of HA35k and rapamycin 
disappeared in the HA-L-Rapa profile. The exothermic peak of HA was ascribed 
to the melting of the polymer crystal. The disappearance of this peak indicated 
that the original crystalline HA structure was disrupted. In addition, the 
dehydration peak of HA shifted to a lower temperature (around 100 °C), 
indicating that the interaction between water and polymer decreased with 
conjugation of the hydrophobic rapamycin. The endothermic peak of rapamycin 
shifted to a higher temperature (near 210 °C). The enthalpy (ΔH) was calculated 
by integrating over the endothermic peak area. For 1.14 %, 2.21 % and 4.78 % 
(w/w) drug loaded HA, the ΔH was 33.6 ± 0.95, 53.58 ± 0.83 and 65.96 ± 2.81 
J/g, respectively. This demonstrated that the degree of thermal stability of HA-L-
Rapa is decreased with increased drug loading degree. 
4.3.3.4 TGA  
Thermogravimetric analysis showed that the drug-polymer conjugates were 
stable up to 200 °C, when degradation began (Fig. 4). 
There were two transition regions during the decomposition process. For the 
non-drug conjugated HA, the 6.402 % weight lost at approximately 100 °C was 
consistent with the expected water content of HA. The maximum decomposition, 
72.24 % wt, occurred at 235.72 °C which is consistent with polymer 
decomposition. The temperature of maximum degradation decreased with 
increasing drug loading: 224.14 °C for the 1.14 % (w/w) conjugate, 218.35 °C for 
the 2.2 % (w/w) conjugate, and 216.61 for the 4.78 % (w/w) conjugate. 
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Fig. 4: TGA analysis of HA35k and different loading degree HA-L-Rapa. (A) HA35k; (B) 
HA-L-Rapa 1.14 % (w/w %); (C) HA-L-Rapa 2.21 % (w/w %); (D) HA-L-Rapa 4.78 % 
(w/w %). 
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The first transition region corresponds to the loss of water bonded to the HA 
molecule. The degradation temperatures of HA-L-Rapa conjugates were lower 
and the weight losses were smaller compared to HA35k. This trend is consistent 
with the DSC data, and it can be explained by that the water content was 
decreased when the hydrophobic molecules were conjugated on the HA surface. 
The second transition region is polymer degradation. The TGA plots illustrated 
that the weight loss was decreased with higher drug conjugated HA. This is also 
consistent with DSC data that the enthalpy at this region was increased with the 
drug loading degree. 
4.3.4 Flow Cytometry  
    The expression of CD44 receptors on MDA-MB-468 cells was studied by flow 
cytometry. The cells were directly stained with PE-CD44 antibody and the PE-
IgG1 isotope was used as a control (Fig. 5). Protein quantification by flow 
cytometry demonstrated that the percentage of CD44 positive cells in MDA-MB-
468 and 4T1.2neu was 99.92 % and 89.59 %, respectively. When MDA-MB-468 
CD44 binding sites were blocked with H-CAM, the percentage of active sites 
decreased to 0.57 %. This result indicated that H-CAM can be used as an 
inhibitor to block the receptor-mediated endocytosis of HA.      
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Fig. 5: Flow cytometry analysis of available CD44 receptor binding sites on the cell 
surface. (A) MDA-MB-468 stained with PE anti-CD44 antibody (dark grey) and PE IgGI 
isotope (light grey); (B) MDA-MB-468 treated with H-CAM and stained with PE anti-
CD44 antibody (dark grey) and PE IgGI isotope (light grey); (C) 4T1.2neu stained with 
PE anti-CD44 antibody (dark grey) and PE IgGI isotope (light grey). 
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4.3.5 In Vitro Efficacy Study  
4.3.5.1 Cytotoxicity  
Cytotoxicity of unconjugated rapamycin and HA-L-Rapa at different 
concentrations was determined in MDA-MB-468 cells with or without H-CAM 
treatment (Fig. 6). In CD44 positive MDA-MB-468 cells, HA-L-Rapa decreased 
cell-viability by 8.72 % compared to rapamycin (p = 0.027) at 10 µM. The addition 
of H-CAM blocked CD44-mediated uptake and there was no significant 
difference in cell viability between HA-L-Rapa and the free drug (p = 0.065). 
4.3.5.2 Cellular Uptake Analysis  
MDA-MB-468 cells with or without H-CAM in a 12-well plate were treated with 
free rapamycin or HA-L-Rapa at a drug concentration of 10 µM. Drug 
concentration in the cell culture medium was analyzed by HPLC (Fig. 7). In CD44 
positive cells, the polymer drug conjugate significantly improved the drug uptake 
by 3.2 times compared to the free rapamycin (p = 0.012). When CD44 was 
blocked with H-CAM, there was no difference in rapamycin uptake between the 
free drug and polymer conjugate groups (p = 0.13).     
4.3.6 Pharmacokinetics Evaluation 
The pharmacokinetics of free rapamycin (i.p.) and HA-L-Rapa (s.c.) were 
compared in female Sprague-Dawley rats (n = 3). A two-compartment 
pharmacokinetic model was selected to describe the exponential nature of the 
pharmacokinetics disposition of the drug (Fig. 8). The area under the plasma 
concentration time curve (AUC0

∞) of rats administrated with HA-L-Rapa was 
2.78-fold greater than that of the free drug, and the concomitant total body 
clearance was 2.09-fold slower (Table 3).  
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Fig. 6: Cell viability assay of free rapamycin and HA-L-Rapa in MDA-MB-468 cells 
(A) CD44 positive cells and (B) with H-CAM blocking of CD44 (Mean ± SD) (*, p < 0.05). 
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Fig. 7: HA-L-Rapa formulation improved CD44+ cells’ uptake of the drug (mean ± SD) 
(*: p < 0.05). 
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Fig. 8: Plasma rapamycin concentration versus time disposition (Mean ± SD, n = 3). 
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Table 3: Pharmacokinetic parameters after i.p. free rapamycin and s.c. HA-L-Rapa. 
(Mean ± SD, n = 3) (*: p < 0.05; **: p < 0.01) 
 
Parameters Unit Free Rapamycin i.p. HA-L-Rapa s.c. 
Vd L/kg 37.68 ± 15.49 12.88 ± 5.24* 
AUC0

∞ (µg·h)/mL 2.36 ± 0.46 6.57 ± 0.92** 
Cl L/(kg·h) 4.23 ± 0.95 2.02 ± 0.73** 
Cmax ng/mL 172.86 ± 69.06 544.84 ± 123.56* 
t1/2 h 10.49 ± 3.76 27.95 ± 13.33* 
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4.3.7 Animal Survival and Tumor Suppression Studies 
BALB/c mice were inoculated with 4T1.2neu cells to evaluate the attenuation 
effect of HA-L-Rapa on overall tumor progression. The median survival times of 
control, free rapamycin and HA-L-Rapa treatment groups were 17, 15 and 22 
days, respectively (Fig. 9). Regression analysis demonstrated that HA-L-Rapa 
treatment was associated with significantly longer survival of mice with mouse 
mammary carcinoma compared with both the untreated control group (p = 0.047) 
and free drug treatment group (p = 0.018). 
The in vivo 4T1.2neu breast cancer model also illustrated a significant 
decrease (p = 0.049) in tumor volume on day 20 in BALB/c mice treated with HA-
L-Rapa (10 mg/kg equivalent rapamycin) compared with that of the control group. 
Free rapamycin (10 mg/kg) also decreased tumor volume; however, the 
difference was not significant (p = 0.056).  
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Fig. 9: HA-Rapa significantly improved animal survival (A) and suppressed tumor 
progression (B) in BALB/c mice with 4T1.2neu breast cancer (Mean ± SD) (n = 5; *, p < 
0.05). 
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4.3.8 Tissue Distribution 
Twelve hours after s.c injection of HA-L-Rapa, the drug concentrations in 
tumor, lymph and lung were 1.56, 2.78 and 3.23-fold greater than the free drug 
treatment group (Table 4). The order of drug concentrations for the control group, 
free rapamycin (i.p.), were tumor > lymph > lungs > kidneys > heart > liver > 
muscle > spleen > brain. The drug concentration of HA-L-Rapa (s.c.) formulation 
were lungs > lymph > tumor > spleen > muscle > liver > kidneys > heart > brain. 
4.4 Discussion 
In this study, we described the use of hyaluronic acid as a drug delivery carrier 
that can enhance the efficacy of the conjugated rapamycin against CD44 positive 
cancer cells. Previously in our lab, we showed that the t50% of the lymphatic drainage 
of medium length HA (35 kDa – 74 kDa) to the axillary lymph node was 15 -17 h and 
the tmax was around 2 h (31). The release half-life of rapamycin from HA-
Temsirolimus in PBS was approximately 4 h. The bulk of the drug would therefore be 
released before the polymer cleared from the target site. However, the sustained 
release characteristics can be improved by using 3-amino-4-methoxy-benzoic acid 
instead of ADH as a linker to conjugate the drug (HA-L-Rapa). This can be explained 
as HA-Temsirolimus was prepared using an unhindered ester, which allows rapid 
hydrolysis and release of the drug in water and serum. In comparison, the ester 
bond in HA-L-Rapa is stabilized by the para site methoxy group on the benzene ring 
that served as a strong electron donating group and reduced the hydrolysis rate. In 
addition, the ester bond in HA-L-Rapa was more hindered and the drug was in a 
more rigid condition. These structural configurations provided a more hydrophobic 
environment than that of HA-Temsirolimus, which may limit access by serum  
144 
 
Table 4: Mean concentration of rapamycin in mice tissues measured at 12 h post 
administration of 10 mg/kg equivalent rapamycin by i.p. (free rapamycin) and s.c. (HA-L-
Rapa) injection.  (Mean ± SD, n = 5) (*, p < 0.05; **, p < 0.01)  
Tissue 
Free Rapamycin 
(µg/g) 
HA-L-Rapa (µg/g) 
Brain 107.69 ± 37.25 195.01 ± 48.56* 
Kidneys 469 ± 27.27 495.04 ± 349.05 
Tumor 1237.01 ± 256.20 1931.84 ± 195.46** 
Lymph 705.28 ± 115.87 1972.78 ± 634.80** 
Heart 440.73 ± 81.57 358.88 ± 110.31 
Liver 378.72 ± 40.56 565.56 ± 54.06* 
Lungs 617.53 ± 298.54 1990.00 ± 634.80** 
Muscle 315.56 ± 154.12 927.64 ± 453.48* 
Spleen 183.91 ± 66.46 1386.31 ± 342.71** 
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esterase. The release half-life was increased to approximately 36 h in serum 
supplemented PBS. This could provide a sustained release of the drug at the 
targeted tissue and minimize the systemic toxicity by reducing the necessary drug 
dose and limiting drug non-targeted tissue exposure. 
Low molecular weight HA (less than 10 kDa) was reported to reversibly bind CD44 
and is associated with immunogenicity. However, higher molecular weight HA 
(greater than 30 kDa) binds irreversible to CD44 due to the increased multivalent 
interactions (32). The 35-kDa HA used in this study has approximately 87 D-
glucuronic acid repeating units. The 2.6 % w/w loading is equivalent to one 
rapamycin per one polymer chain, so over 98 % of the glucuronic side chains are 
available for binding CD44.  
The in vitro results of the antibody blocking studies showed that the internalization 
of HA-drug conjugate was inhibited by the H-CAM CD44 inhibitor, which blocked 
endocytosis and CD44 specific uptake. Since HA-L-Rapa entered the cells through 
an endocytic pathway, inhibition of this pathway resulted in a reduction of the 
internalization degree of the polymer drug conjugate. Cellular uptake of the lipid 
permeable free drug is driven by a concentration gradient. After equilibrium is 
established, no more drug is able to enter cells, hence inhibition of CD44 receptor 
did affect free rapamycin uptake by MDA-MB-468 cells. Receptor mediated transport 
of HA-L-Rapa improved drug delivery in CD44 positive cells and the cytotoxicity was 
also significantly enhanced. These results also indicated that conjugate of rapamycin 
does not inhibit the HA-CD44 interaction at the amounts studied; this strategy could 
be utilized as a novel drug delivery platform for targeted chemotherapy with 
rapamycin. 
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This study limited rapamycin to i.p. injection and the conjugate to local s.c. 
administration. Rapamycin is poorly water soluble and no safe i.v. formulation has 
been reported. Clinical trials of i.v. rapamycin resulted in injury (swelling and focal 
lesion) at the injection site, lymphoid atrophy and periarterial edema in the heart, 
liver (FDA NDA 21-083). Our own previous rat studies demonstrated significant 
morbidity and a 40 % mortality of i.v. rapamycin in rats (30). Rapamycin cannot be 
given subcutaneously repeatedly and safely as the free drug. Myckatyn reported 
skin ulceration in mice administrated 2 mg/kg rapamycin (one fifth of our dose), and 
given the ulceration potential of the 4T1.2neu model, this control study was not 
permitted by institutional animal care guidelines (33). Therefore, in this study, 
intravenous administration of rapamycin was not investigated.  
The pharmacokinetics profile of s.c. HA-L-Rapa was greatly altered compared to 
the standard i.p. free rapamycin formulation. The high value of Vd of free rapamycin 
results from its lipophilicity and thus high tissue distribution. The HA conjugate 
significantly reduced the volume distribution possibly by minimizing nonspecific 
tissue binding. The increased AUC and slower clearance rate of s.c. HA-L-Rapa are 
consistent with the sustained release of the drug from the conjugate.  
HA targets to CD44 receptors and could specifically bind to CD44 positive cells. 
HA molecules are uptake by the cells through CD44 receptor-mediated endocytosis 
followed by lysosomal degradation. The distribution of rapamycin in the HA-L-Rapa 
treated mice was mainly in the tumor. The significant improvement in exposure drug 
in target tissues by HA-L-Rapa suggested that a lower dose of rapamycin may 
achieve a therapeutic effect.  
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In addition, the 4T1 is a highly metastatic cancer cell line (34). At necropsy, lung 
metastases were observed in 5/5 of the free rapamycin group and only 1/5 of the 
HA-L-Rapa group. This is consistent with that more drug was detected in HA-L-Rapa 
treated animals’ lungs. The lung accumulation can be explained by the prevalence of 
four major HA-binding proteins that potentially contributed to lung pathology 
regulation: CD44, toll-like receptor (TLR4), HA-binding protein 2 (HABP2) and 
receptor for HA-mediated motility (RHAMM) (35). Meanwhile, HA constitutes the 
major glycosaminoglycan in lung tissue and it has diverse function in lung 
homeostasis and pulmonary disease. 
HA is cleared from tissues mainly by the lymphatic system due to the presence of 
lymphatic endothelial hyaluronan receptor, LYVE-1 (36). The expression of LYVE-1 
is largely restricted to lymphatic vessels and splenic sinusoidal endothelia cells (37). 
The LYVE-1 receptor has a 41 % homology to the HA-binding CD44 receptor. This 
provided an additional HA targeting mechanism. It is consistent with HA-L-Rapa 
treated mice, where more drug accumulated in the lymph node and the spleen 
compared to the free drug treatment group. 
The breast cancer cell line, 4T1, has an inherent propensity of ulceration (38). Our 
data illustrated that HA-L-Rapa treatment significantly inhibited tumor growth and 
diminished the incidence of ulcerated tumor in mammary carcinoma bearing mice. 
The free rapamycin treatment group showed smaller tumor sizes compared to the 
non-treatment group. However, the animals were sacrificed due to the presence of 
hemorrhagic skin ulcers and there was no statically significant survival benefit 
compared to saline.  
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Rapamycin is a promising therapeutic agent with both immunosuppressant 
(mTOR inhibitor) and anti-tumor activities. The immunosuppressant effect of 
rapamycin comes from the inhibition of T and B cell proliferation (39, 40), which is 
the same mechanism of anticancer activity. However, based on currently available 
evidence, the anti-neoplastic activity is more dominant than that of 
immunosuppressant effects (41). In our study, we developed a formulation that can 
target the drug specifically to the tumor and lymphatic tissue via a CD44 interaction. 
This could further minimize the systemic immunosuppressant activity of rapamycin 
and augment the anti-cancer effects of the drug.    
4.5 Conclusion 
    We have developed a novel HA-rapamycin conjugate for treating localized CD44 
positive cancer. To conjugate rapamycin to HA, two formulation strategies were 
developed and compared. We found that the polymer-drug conjugate prepared by 3-
amino-4-methoxy-benzoic acid released the drug in a sustained fashion. In vitro cell 
line based studies showed that HA-L-Rapa entered the cells via CD44 mediated 
endocytosis. In vivo animal studies indicated that HA-L-Rapa improved animal 
survival rate and suppressed tumor progression in BALB/c mice. These results 
suggest that the HA rapamycin conjugate could be used as a potential therapeutic 
agent for CD44 positive cancers.  
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155 
 
5.1 Introduction 
Doxorubicin (DOX), also known as Adriamycin, is an anthracycline antibiotic with 
anti-cancer activity. DOX is isolated from Streptomycin peucetius and it is a 14-
hydroxyalted congener of daunorubicin. It has been commonly used in the treatment 
of a wide variety of cancers, including ovarian cancer (1), bone and soft tissue 
sarcomas (2), lymphoma (3) and adrenocortical carcinomas (4). DOX can prevent 
DNA replication by blocking topoisomerase II activity and ultimately inhibiting protein 
synthesis. The planar aromatic chromophore of DOX molecule intercalates between 
two pairs of nucleic acids; thus, DNA transcription is blocked. The crystal structure of 
DOX-DNA complex showed that the six-membered duanosamine sugar sits in the 
DNA double helix minor groove and interacts with flanking base pairs adjacent to the 
intercalation site (5, 6). 
DOX is a substrate of the P-glycoprotein (P-gp) efflux pump and cytochrome 
P450. Due to low GI absorption and first-pass metabolism, the oral bioavailability of 
DOX is only approximately 5 %. Therefore, DOX is formulated as hydrochloride salt 
and administrated by intravenous injection.  
Quercetin is an important dietary flavonol derived from plants, such as fruit and 
vegetables. Recent studies showed that quercetin has anti-cancer, anti-viral and 
anti-inflammation activities (7, 8). Quercetin could induce apoptosis in certain types 
of cancer cells, such as H460 lung cancer cells (9), MDA-MB-231 and AU565 breast 
cancer cells (10), PC-3 and LNCaP prostate cancer cells (11), human 232B4 chronic 
lymphocytic leukemia cells (12) and C6 glioma cells (13). 
The combination chemotherapy of DOX and quercetin showed significant promise 
in cancer treatment. When drugs that work by different mechanisms are combined, it 
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could decrease the likelihood of drug resistant development, and minimize the 
intolerable side effects in patients. The combination of DOX and quercetin studies 
indicated that quercetin could enhance the sensitivity of tumor cells, such as breast 
cancer MCF-7 and liver cancer SMMC7721, to the chemical drug and selectively 
induce apoptosis in cancer cells (14, 15). In addition, quercetin was reported as an 
inhibitor of both CYP3A4 enzyme and P-gp, which would minimize P-gp-mediated 
efflux and drug lost in first past metabolism (16). Besides, intraduodenally 
administration of quercetin in rats showed that quercetin and its deviates can be 
absorbed directly through intestinal cells and a higher drug concentration in lymph 
than in plasma was observed (17). It may provide a target delivery mechanism of the 
conjugated drug. 
The co-administration of quercetin with anti-cancer drugs was reported as an oral 
bioavailability enhancing strategy. The absolute bioavailability of paclitaxel in 
quercetin pretreated rats was significantly higher than the control group, and  both 
the elimination half-life and mean residence times of the drug were significantly 
slower (18). Besides, both the absolute and relative bioavailabilities of DOX by orally 
co-administered with quercetin were also found can be significantly improved (16).  
In this study, a novel doxorubicin-quercetin prodrug was synthesized. Chemical 
and biological properties were characterized. Pharmacokinetics were examined in 
Sprague-Dawley rats.   
5.2 Materials and Methods 
5.2.1 Materials 
    Doxorubicin-HCl, 2 mg/mL sterile isotonic solution, was bought from Bedford 
Laboratories (Bedford, OH). Quercetin was purchased from INDOFINE Chemical 
157 
 
Co. (Hillsborough Township, NJ). H-Gly-OtBu-HCl was gotten from Bachem 
Americas Inc. (Torrance, CA). The chemical solvents were obtained from Fisher 
Scientific (Lenexa, KS). NMR spectra were collected with a 400-MHz Bruker, and 
the mass spectra were obtained by electrospray ionization mass spectrometry 
(ESI-MS). 
5.2.2 Synthesis of Doxorubicin-Quercetin Prodrug 
The synthetic scheme of the doxorubicin-quercetin prodrug is shown in Fig. 1. 
Compound 1. All the glassware were flame dried and protected under dry 
argon. All the organic solvents were dried by distillation. In a round bottom flask, 
3 mmol of H-Gly-OtBu-HCl, 3.3 mmol of Bis(4-nitrophenyl) and 6 mmol of N,N-
Diisopropylethylamine (DIPEA) were dissolved in a mixture of THF (20 mL) and 
DMF (10 mL). The reaction was stirred at ambient temperature under dry argon 
for 24 h. Then, 3 mmol of quercetin was added. The solution was stirred at 
ambient temperature for an additional 24 h. After the reaction, the organic phase 
was concentrated under reduced pressure. The residue was purified by silica gel 
column chromatography and eluted with dichloromethane (DCM)-acetone (6:1) to 
furnish the title compound as a yellow solid (0.9 g, yield: 63.85 %). 
Compound 2. Compound 1 (0.9 g) was dissolved in 10 mL of DCM on ice and 
4 mL of trifluoroacetic acid (TFA) was added gradually. The reaction was stirred 
at ambient temperature for 2 h. The yellow precipitate was filtered and washed 
with DCM and acetone (0.443 g, yield: 49.26 %). 
Compound 3. Doxorubicin HCl solution (2 mg/mL, 2.5 mL) was lyophilized. 
Compund 2 (10 mg, 2.5 eq), DIPEA (15 µL, 10 eq) and HATU (7.4 mg, 2.5 eq) 
were dissolved in 5 mL of DMSO. After 30 min, 5 mg of DOX lyophilized powder 
158 
 
was added. The reaction was stirred at ambient temperature for 24 h. The final 
product was purified by HPLC (Rainin Instrument Inc., Woburn, MA) with a 
programmable absorbance detector (Applied biosystems®, Bedford, MA) and a 
reverse phase semi-prep column (Phenomenex Luna® 10 µm, 250 × 10 mm, 
Torrance, CA). The chromatography conditions were a mobile phase A of 0.1 % 
formic acid in ddH2O and B of 0.1 % formic acid in methanol (MeOH) at a flow 
rate of 6 mL/min. The gradient program was i) a linear gradient from 50 % to 
90 % solvent B over 10 min; ii) 8 min with 90 % solvent B; iii) a liner gradient from 
90 % to 10 % solvent B over 2 min; and iv) 5 min with 10 % solvent B. The 
retention time of the final product was 11.4 min.  
5.2.3 In vitro drug release  
    The prodrug was dissolved in PBS supplemented with 10 % FBS and 
placed in a 37 °C water bath. After pre-determined time intervals, 100-µL aliquots 
from the sample tubing were analyzed by HPLC with fluorescent detector (ex/em 
480/590). The release scheme of DOX and quercetin from DOX-Pro is shown in 
Fig. 2.   
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Fig. 1: Synthetic scheme of doxorubicin-quercetin prodrug. 
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Fig. 2: The scheme of DOX and quercetin release from DOX-Pro. 
 
 
 
 
 
 
 
161 
 
5.2.4 Cellular uptake of doxorubicin by MDCK-MDR cells 
Multi-drug resistant canine kidney cells (MDCK-MDR) were maintained in high 
glucose Dulbecco’s modified eagle medium (DMEM) with 1× L-Glutamine and 
sodium pyruvate that was supplemented with 10 % FBS, 1× non-essential amino 
acid and 1× penicillin-streptomycin. Cells were seeded onto poly L-lysine pre-
coated glass coverslips (BD, Franklin Lakes, NJ) in a 12-well culture plate at a 
density of 5000 cells/well. After 12 h, the cells were treated with 50-nM free DOX, 
or DOX-quercetin mixture, or DOX prodrug along with 3 µg/mL DAPI at 15 min 
prior to cell imaging.  After the treatment, the cells were washed three times with 
PBS. The live cells were rapidly imaged on a Nikon Eclipse 80i epiflurescence 
microscope (Melville, NY) with a 20 × 0.75 NA objective and a Hamamatsu 
ORCA ER digital camera (Houston, TX). The GFP filter set (Nikon, NY) was used 
to image the fluorescence signal from DOX. All the images were taken with 
identical instrument settings and scaled equally so that fluorescence intensity 
could be compared between independent images and quantified accurately.  
The cellular uptake and accumulation of DOX in MDCK-MDR cells was 
quantified using HPLC. The cells were seeded in a 12-well plate at a 
concentration of 10,000 cells/well. After the cells attached to the surface, 1-µM 
DOX, DOX quercetin mixture or DOX prodrug was added. After a 6-h treatment, 
the supernatant was removed and analyzed. 
5.2.5 Pharmacokinetic study 
    Female Sprague-Dawley rats were administrated free DOX and doxorubicin-
quercetin prodrug orally at the dosage of 10 mg/kg. Whole blood was withdrawn 
at 0 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 12 h, 24 h and 48 h after dosing. The 
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whole blood was centrifuged, and the plasma was collected. Urine samples were 
collected at 0 h, 2 h, 6 h, 12 h, 24 h, 48 h and 72 h. The drug concentration was 
analyzed by a fluorophotometer (RF-5301 PC, Shimadzu). The PK parameters 
were calculated by WinNonlin®. 
5.2.6 Statistical analysis 
GraphPad Prism 5 software was used for statistical analysis. A t-test was used 
for statistical analysis between two means. In all comparisons, statistical 
significance was set at p ≤ 0.05. 
5.3 Results 
5.3.1 DOX-Quercetin Prodrug Synthesis 
Quercetin-Gly-tBu was synthesized according to the reference (19). High 
resolution mass spectrometry (ESI) Calc’d for C22H20NO10 (M-H)
-: 458.1087; 
Found: 458.0047. 1H-NMR (Acetone-d6, 400 MHz): δ = 12.06 (s, 1H), 9.23(bs, 
1H), 7.99 (d, J = 2.2 Hz, 1H), 7.96 (dd, J = 8.6, 2.1 Hz, 1H), 7.06 (d, J = 8.7 Hz, 
1H), 6.99 (t, J = 6.6 Hz, 1H), 6.46 (t, J = 2.1 Hz, 1H), 6.21 (t, J = 2.1 Hz, 1H), 
3.86 (d, J = 6.0 Hz, 2H), 1.43 (s, 9H). 
Quercetin-Gly-COOH 1H-NMR 1H-NMR (DMSO-d6, 400 MHz): δ = 12.69 (bs, 
1H), 12.44 (s, 1H), 10.81(bs, 1H), 10.38 (bs, 1H), 9.56 (s, 1H), 8.02 (t, J = 6.8 Hz, 
1H), 7.91 (dd, J = 8.6, 2.3 Hz, 1H), 7.88 (d, J = 2.2 Hz, 1H), 7.06 (d, J = 8.6 Hz, 
1H), 6.47 (d, J = 2.0 Hz, 1H), 6.21 (d, J = 2.0 Hz, 1H), 3.77 (d, J = 6.1 Hz, 2H). 
HRMS (ESI) Calcd for C18H12NO10 (M-H)
-: 402.0461; Found: 402.0419. 
Quercetin-Gly-Dox 1H-NMR (DMSO-d6, 400 MHz): δ = 8.32 (s, 1H), 7.94 (t, J 
= 6.4 Hz, 1H), 7.90 (d, J = 1.2 Hz, 1H), 7.88 (s, 1H), 7.79 (s, 1H), 7.71 (s, 1H), 
7.15 (d, J = 8.4 Hz, 1H), 7.06 (d, J = 8.4 Hz, 1H), 6.46 (s, 1H), 6.19 (s, 1H), 5.50 
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(s, 1H), 5.23 (s, 1H), 4.97 (s, 1H), 4.87 (s, 2H), 4.57 (s, 1H), 4.16 (s, 1H), 4.00-
3.89 (m, 3H), 3.07 (s, 3H), 3.00 (s, 1H), 2.92 (s, 3H), 2.78 (d, J = 9.6 Hz, 1H), 
2.68 (d, J = 6.4 Hz, 1H), 2.21-2.11 (m, 2H), 3.32 (s, 3H), 2.99-2.89 (m, 2H), 2.84-
2.56 (m, 1H), 2.37-2.21 (m, 3H), 1.51-1.41 (m, 1H), 1.24 (s, 1H), 1.13 (d, J = 7.6 
Hz, 3H). HRMS (ESI) Calcd for C45H39N2O20 (M-H)
-: 927.2096; Found: 927.2086. 
5.3.2 Drug release study 
The in vitro drug release profile is shown in Fig. 3. The release of DOX was 
due to the enzyme digestion of the amide bond. The release of DOX from the 
prodrug showed a first-order kinetic profile and the t1/2 was approximately 60 h. 
Quercetin was released from the prodrug conjugate by hydrolysis of the 
carbamate bond. The quercetin exhibited second-order kinetics in aqueous 
medium and the release half-life was over 100 h.  
5.3.3 Cellular uptake analysis 
Confocal microscopy was used to examine if the prodrug would improve DOX 
uptake by P-gp positive cells. More fluorescence signal was detected in DOX 
quercetin mixture and DOX prodrug treatment groups (Fig. 4). The images were 
analyzed by ImageJ (Fig. 5). After 5 min treatment, there was no significant 
improvement of drug uptake by the cells treated with DOX-quercetin mixture 
compared to that of the free DOX (p = 0.595). However, the fluorescence signal 
was significantly enhanced in the cells treated with DOX prodrug (p = 0.0123). 
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Fig. 3: In vitro drug release of DOX and quercetin from DOX prodrug. 
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Fig. 4: Fluorescence imaging study of cell uptake of doxorubicin by MDCK-MDR cells. 
(A) cells were treated with 50 nM free DOX; (B) cells were treated with 50 nM DOX and 
50 nM quercetin; (C) cells were treated with 50 nM DOX prodrug. 
 
 
 
 
 
 
166 
 
DOX DOX-Q Mix DOX Prodrug
0
5
10
15
20
25
*
R
F
U
/C
e
ll
 (
x
1
0
5
)
     
Fig. 5: The fluorescence signals of the images of MDCK-MDR cells treated by DOX, 
DOX-quercetin and DOX prodrug analyzed by ImageJ. (Mean ± SD, *: p < 0.05) 
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The drug uptaken by the cells quantified by HPLC is shown in Fig. 6. The 
prodrug formulation significantly improved drug uptake compared to both the free 
DOX and DOX-quercetin mixture. This is consistent with the fluorescence 
imaging study. 
5.3.4 Pharmacokinetics in Rat Serum 
The pharmacokinetics of oral administration of free DOX and doxorubicin-
quercetin prodrug were compared in female Sprague-Dawley rats. 
Pharmacokinetics of free DOX and DOX-Pro in rat serum and urine are shown in 
Fig. 7. The serum pharmacokinetics parameters were calculated and listed in 
Table 1. The area under the plasma concentration time curve (AUC0

∞) of rat 
administrated with the prodrug was 7.37-fold greater than that of the free DOX. 
The clearance was 2.87-fold slower. 
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Fig. 6: Prodrug formulation improved drug uptake by P-gp positive cells. (Mean ± SD, *: 
p < 0.001) 
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Fig. 7: Concentration-time profiles of DOX in rat serum after oral administration (mean ± 
SEM, n = 2). 
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Table 1: Pharmacokinetic parameters of DOX and DOX-Pro in rats (Mean ± SD, n = 2) 
(* p < 0.05, ** p < 0.01). 
Parameters Unit DOX DOX-Pro 
Cmax µg·mL
-1 0.748 ± 0.0767 5.516 ± 0.410** 
t1/2 (Serum) h 13.412 ± 1.306 7.817 ± 0.318 
AUC (Serum) µg·h·mL-1 8.732 ± 0.154 26.342 ± 2.438* 
Fe % 2.739 ± 0.283 4.488 ± 0.287* 
Cl mL·h-1·kg-1 340.735 ± 18.431 118.687 ± 8.157** 
Clrenal mL·h
-1·kg-1 9.856 ± 1.663 5.397 ± 0.013 
ClNR mL·h
-1·kg-1 347.191 ± 22.191 115.383 ± 8.011* 
Vz/F mL 6628.05 ± 998.48 1342.22 ± 146.52* 
MRT h 20.487 ± 2.230 9.452 ± 0.329* 
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5.3.5 Pharmacokinetics in Rat Urine 
    Following orally administration of DOX or DOX-Pro, the rate elimination plots, 
total amount excreted urine plots and the amount remaining to be excreted 
(ARE) plots are shown in Fig. 8. The fraction excreted unchanged of DOX from 
DOX-Pro formulation (4.49 ± 0.29 %) was increased by 1.64-fold than the naked 
drug. In addition, there was no significant difference was observed between 
Clrenal. However, the ClNR was reduced by 3-fold. The total amount excreted plot 
indicates that DOX was excreted in a higher amount in prodrug form compared to 
the free DOX. 
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Fig. 8: (A) Urinary rate plot; (B) Total amount excreted in urine plot; (C) amount 
remaining to be excreted in urine (ARE) of rats after oral administration of DOX or DOX-
Pro at a dose of 10 mg/kg (Mean ± SD, n = 2). 
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5.4 Discussion and Conclusion 
The first-pass effect, or first-pass metabolism, is when orally administrated drugs 
are degraded or altered by gastrointestinal and hepatic enzymes, resulting in greatly 
reduced active drug form reaching the general systemic circulation. Bioavailability is 
defined as the fraction of orally administered drug absorbed unchanged into the 
systemic circulation. The oral bioavailability of a drug could be significantly reduced 
by induction of the first-pass effect. 
P-gp, also known as muti-drug resistance protein 1, is a glycoprotein that is 
extensively distributed and expressed in the intestinal epithelium (20). It is a member 
of the ATP-binding cassette transporter superfamily. This transmembrane protein is 
an ATP-dependent efflux pump with broad substrate specificity. The P-gp transporter 
consists of two domains, the transmembrane domain and the nucleotide binding 
domain. The transmembrane domain recognizes a wide variety of substrates and 
undergoes a conformational change to pump out the substrate. The nucleotide 
binding domain is the site for ATP binding and hydrolysis. The expression of P-gp in 
intestinal compartments can reduce body absorption of drugs that are the substrates 
of P-gp, such as DOX. Therefore, drug oral bioavailability is reduced and no 
therapeutic plasma concentration of the drug can be achieved.  
Qian et al. showed that quercetin was tightly bound to the nucleotide binding 
domain of P-gp and directly inhibited its ATPase activity. Homology modeling of the 
nucleotide binding site was modeled, and then the quercetin was docked into the 
modeled structure. They demonstrated that the ATP binding sites were spatial 
coordinates overlapped with quercetin and that the quercetin was competing for 
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binding. There are 14 putative hydrogen bonds observed between the quercetin and 
the binding site (21). 
Another factor that contributes to low oral bioavailability of free DOX is that DOX 
is also a substrate of CYP3A4 enzyme (22). CYP3A4 is a member of the 
cytochrome P450 family and involves in the oxidation of the largest range of 
substrates of all the CYPs. It is present in the largest quantity of all the CYPs in the 
liver. There is an estimate that half of the drugs on the market can be metabolized by 
CYP3A4. Quercetin is not only an inhibitor of P-gp, but also a substrate of CYP3A4. 
Choi et al. showed that the combination of quercetin with doxorubicin significantly 
improved oral bioavailability of doxorubicin in rats (16). The activity of both P-gp and 
CYP3A4 were dramatically suppressed by quercetin. 
There is a clinical evidence that antioxidant may alter the effectivity of the 
chemotherapy treatment (23, 24). On the one hand, some studies showed that 
taking antioxidants during chemotherapy can be helpful (25). This is because most 
cytotoxic chemotherapy drugs generate reactive oxygen species (ROS) and cause 
high levels of oxidative stress in the tumor and normal tissues. Clinical studies 
showed that the most dangerous side effect of DOX HCl solution is heart damage in 
patients (26). The free radicals generated by DOX are the key factor contributing to 
its severe cardiotoxic side effect (27). The scavengers of those free radicals can 
inhibit DOX induced cardiomyocyte apoptosis and minimize systemic toxicities (28). 
On the other hand, some suggest that using anti-oxidants should be avoided when a 
patient is under cancer chemotherapy. Studies showed that antioxidants, such as 
quercetin, may protect cancer cells from apoptosis and enhance cell viability (29). 
Since both anti-cancer activity and protection effect were reported, the working 
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mechanism of quercetin may be cell line specific. Thus, cancer patients should be 
carefully considered for traditional phytotherapy during cancer treatment. 
In this study, quercetin was chemically conjugated to DOX. The DOX was 
released from the prodrug by peptidase cleavage, and the quercetin was released 
by hydrolysis reaction. Before the prodrug converted into the free DOX and 
quercetin, the bulky structure might further reduce the binding affinity of DOX to the 
transmembrane domain of P-gp compared to the free DOX. In addition, quercetin 
was conjugated with a linker that could provide enough free space. The binding of 
quercetin to P-gp at the nucleotide binding domain, which is inside the cytoplasm, 
may not be hindered. In addition, the prodrug may change the pharmacokinetics and 
drug disposition of both DOX and quercetin. The protecting effect of quercetin in 
certain types of cancer may be altered. 
In rat pharmacokinetics study, the DOX-Pro formulation significantly improved 
serum t1/2, AUC, and Fe. Following oral administration of the prodrug, the non-renal 
clearance was significantly decreased. It can be explained by the quercetin 
protection mechanism against the enzymes in the liver. Moreover, the total body 
clearance was significantly faster in the DOX-Pro administrated rats than that of the 
free DOX. It indicates that the drug accumulation in the body can be reduced by the 
prodrug formulation, and the DOX-Pro may further lower non-specific toxicity caused 
by DOX in the body. Therefore, the prodrug formulation may serve as a novel form of 
DOX for oral administration with improved bioavailability and altered tolerability.  
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Chapter 6 
Development of a HPLC Method for Separation of Highly Active Compounds from 
Degraded Alternol 
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6.1 Introduction 
Naturally occurring compounds, such as herbal extracts and fermentation 
products, could serve as complimentary medications to improve treatment in many 
cancer patients with minimal side effects (1, 2). Paclitaxel, a mitotic inhibitor used in 
anticancer chemotherapy, was isolated from the bark of the Pacific yew tree, Taxus 
brevifolia, in 1971 (3). Harvesting the drug from the tree bark required killing the tree, 
which had uncertain population, slow growth and unknown future demand. Therefore, 
an alternative and sustainable source was preferred.  
A fermentation technology was developed to produce paclitaxel, using a specific 
Taxus plant cell line in aqueous medium with Penicillum raistrickii, an endophytic 
fungus. This fermentation technology also eliminated the use of hazardous 
chemicals needed in the total synthesis and semi-synthesis of the molecule. In 
response to the success of the Taxus brevifolia bark extract, researchers are still 
looking for unique anti-cancer agents from the yew tree. 
Alternol (Fig. 1A) is a novel fermentation compound from a microorganism called 
Alternaria alternate var. monosporus, which was isolated from the bark of the yew 
tree. Alternol showed anti-proliferating effects and induced apoptosis in mouse 
leukemia cells (4), human gastric carcinoma cells (5) and prostate cancer cells (6). 
The expression level of caspase-3, an apoptosis-related cysteine peptidase, was 
found up-regulated after alternol treatment (7). In addition, alternol showed selective 
anti-cancer effects through modulations of the AMP-activated protein kinase 
signaling pathway (6). 
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Fig.1: (A) Structure of alternol; (B) degradation compound #1 (MW: 700); (C) 
degradation compound #2 (MW: 350); (D) degradation compound #3 (MW: 332). 
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The preparation of alternol from a fermentation process was reported in the patent, 
application US No. 2009/0203775 A1. The cultured microorganism medium was 
extracted with organic solvent twice. The compound from second extraction was 
purified by a chromatography process. To crystalize the product, the desired 
compound was dissolved in ethyl acetate and precipitated in cold petroleum ether.  
The purified alternol from a provider showed multiple peaks on HPLC alluding to 
degradation of the alternol. In this study, a HPLC method was developed to separate 
the active compound(s) from the mixture. 
6.2 Materials and Methods 
6.2.1 Materials 
    Alternol was obtained from Strand Biotech Co. Ltd. (Shantou, China). All the 
solvents, of the highest grade, were purchased from Fisher Scientific (Lenexa, 
KS) or Sigma Aldrich (St. Louis, MO) and were used as received. Mass spectra 
were obtained by electrospray ionization mass spectrometry (ESI-MS). 
6.2.2 HPLC Method Development 
    A Shimadzu LC-2010CHT system (Shimadzu Scientific Instruments, Columbia, 
MD) with a reversed phase column and UV detection at 260 nm was used.  
6.2.2.1 The effects of different organic phases gradients, flow rates and 
column temperatures 
The mobile phases were A of 100 % ddH2O and B of 100 % MeOH. The 
reverse phase column, TSK-GEL® ODS-100Z (Tosho Bioscience LLC, King of 
Prussia, CA) was used. The gradient was i) 5 min with 10 % solvent B; ii) a liner 
gradient from 10 % to 85 % or 75 % solvent B over 5 min; iii) 10 min with 85 % or 
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75 % solvent B; iv) 10 min with 10 % solvent B. The chromatograms are shown 
in Fig. 1. The column temperatures were set at 35 °C. 
The difference between acetonitrile (ACN) and MeOH was studied. The mobile 
phases were A of 100 % ddH2O and B of 100 % ACN. The gradient was i) 5 min 
with 10 % solvent B; ii) a liner gradient from 10 % to 65 % solvent B over 5 min; 
iii) 10 min with 65 % solvent B; iv) 10 min with 10 % solvent B. The 
chromatograms are shown in Fig. 2. The column temperature was set at 35 or 
50 °C. The flow rates were 0.6 mL/min. 
6.2.2.2 The effects of column factors 
    The mobile phases were A of 100 % ddH2O and B of 100 % MeOH. The 
gradient was i) 5 min with 10 % solvent B; ii) a liner gradient from 10 % to 50 % 
solvent B over 5 min; iii) 10 min with 50 % solvent B; iv) 10 min with 10 % solvent 
B. Three additional columns were used: Jupiter® 5 µm C5 300A 150 × 4.6 mm 
(Phenomenex, Torrance, CA); Phenyl Hypersil NCI 2404 (Fisher Scientific, 
Lenexa, KS); Thermo Scientific Hyoersil CPS-2 (Cyano) (Fisher Scientific, 
Lenexa, KS). 
6.2.2.3 The effects of acidic mobile phase modifier 
The mobile phases were A of 0.1 % (v/v) formic acid in ddH2O and B of 0.1 % 
(v/v) formic acid in MeOH. The C18 reverse phase column was a TSK-Gel® 
ODS-100Z. The gradient was i) 5 min with 10 % solvent B; ii) a liner gradient 
from 10 % to 75 % or 65 % solvent B over 5 min; iii) 10 min with 75 % or 65 % 
solvent B; iv) 10 min with 10 % solvent B. The chromatograms were shown in Fig. 
4. The column temperature was set at 50 °C. The flow rate was 0.5 mL/min. 
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6.2.2.4 The effects of basic mobile phase modifier 
    The mobile phase were A of 0.1 % (v/v) TEA and B of 0.1 % (v/v) TEA in 
MeOH. The gradient was i) a liner gradient from 10 % to 90 % over 20 min; ii) 1 
min with 90 % solvent B; iii) 10 min with 10 % solvent B. The flow rate was 0.6 
mL/min. 
6.2.3 Selectivity and Resolution 
Selectivity of the two peaks was calculated as following:  
    α = (tR2-t0)/(tR1-t0)    (1) 
 The fundamental resolution equation was calculated as: 
    Rs = (tR2-tR1)/((0.5×(w1+w2))    (2) 
where tR1 and tR2 are the retention times of two adjacent peaks and w1 and w2 
are their corresponding baseline peak widths. 
Rs also can be calculated using widths at half of the peak height with following 
equation: 
Rs = (tR2 - tR1)/((1.7 × 0.5 × (w0.5,1 + w0.5,2))    (3) 
6.2.4 Cytotoxicity 
Prostate cancer cell line, PC3, was used to test the cytotoxicities of the three 
degraded compounds. Cells were plated in 96-well plate overnight. Then, the 
cells were treated with the purified active components for additional 48 h. The 
proliferation rates of the cells were analyzed by MTT assay using the Cell 
Proliferation kit I (Roche Molecular Biochemicals, Indianapolis, IN). 
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6.3 Results 
6.3.1 The effects of organic solvent contents, flow rates and column 
temperatures. 
Alternol was separated by a C18 TSK-GEL® ODS-100Z column using MeOH 
and ddH2O as the mobile phases with different conditions as shown in Fig. 2. 
Even though lowering the organic phase gradient and reducing mobile phase 
flow rate gave better separation, complete separation could not be achieved by 
using such optimization.  
Acetonitrile (ACN) generated a shorter retention time compared to MeOH (Fig. 
3). With the same gradient, the retention time was around 16 min using MeOH as 
the organic phase with a flow rate of 0.8 mL/min (Fig. 2B), which was 
approximately the same as using ACN with a flow rate of 0.6 mL/min (Fig. 3A). 
This is consistent with ACN’s higher elution strength compared to MeOH. 
By increasing the column temperature from 35 °C to 50 °C, the retention time 
was shorted by approximately 2 min. However, there was no significant 
difference on separation ability. 
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    Fig. 2: (A) Alternol separation using ddH2O/MeOH as the mobile phase. 
Chromatogram condition: flow rate 0.8 mL/min; gradient MeOH 85 % at plateau. 
(B) Alternol separation using ddH2O/MeOH as the mobile phase. Chromatogram 
condition: flow rate 0.8 mL/min; gradient MeOH 75 % at plateau. (C) Alternol 
separation using ddH2O/MeOH as the mobile phase. Chromatogram condition: 
flow rate 0.6 mL/min; gradient MeOH 85 % at plateau. 
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Fig. 3: (A) Alternol separation using ddH2O/ACN as the mobile phase. Column 
temperature: 35 °C; (B) Alternol separation using ddH2O/ACN as the mobile 
phase. Column temperature: 50 °C. 
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6.3.2 The effects of column factors 
Different columns were used for compound separation. The retention time of 
the main peak using a Jupiter® 5 µm C5 300A 150 × 4.6 mm and Phenyl 
Hypersil NCI 2404 column were 10.108 and 14.992 min, respectively (Fig. 4). 
There was no separation of the three compounds and a tailing peak was 
observed.  The peak was wider when using a phenol column compared to the C5 
column. The retention time of using Hyoersil CPS-2 (Cyano) column was 9.125 
min with an asymmetric peak shape (Fig. 4C). 
6.3.3 The effects of acidic modifier 
The major peaks had better separation when 0.1 % TFA was added to the 
mobile phases (Fig. 5). With a lower gradient, a longer retention time was 
observed and the peaks were further isolated. However, there still was not 
complete separation using this strategy. 
6.3.4 The effects of basic modifier 
The separation chromatograms of the compound mixture using ddH2O and 
MeOH with 0.1 % TEA as the mobile phases are shown in Fig. 6. The three 
compounds were completely separated. Each peak was then re-injected into the 
HPLC. After re-injection, the first peak showed only one peak (Fig. 6B). The 
second peak generated three peaks again (Fig. 6C). The third peak gave two 
peaks, the first peak and the third peak (Fig. 6D).  
 
 
 
 
192 
 
 
 
 
193 
 
 
Fig. 4: (A) Alternol separation using a Jupiter® 5 µm C5 300A 150 × 4.6 mm 
column. Flow rate was 0.6 mL/min. (B) Alternol separation using Phenyl Hypersil 
NCI 2404 column. Flow rate was 0.5 mL/min. (C) Alternol separation using 
Thermo Scientific Hyoersil CPS-2 (Cyano) column. Flow rate was 0.2 mL/min. 
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Fig. 5: (A) Alternol separation using ddH2O/MeOH with 0.1 % TFA as the mobile 
phase. MeOH was 85 % at plateau; (B) Alternol separation using ddH2O/MeOH 
with 0.1 % TFA as the mobile phase. MeOH was 75 % at plateau. 
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Fig. 6: (A) Alternol separation using 0.1 % TEA as the mobile phase modifier; (B) 
Peak #1 re-injection; (C) Peak #2 re-injection; (D) Peak #3 re-injection. 
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6.3.5 Selectivity and Resolution 
The selectivity and resolution of the two major peaks of the compound mixture 
by different separation methods were calculated as shown in Table 1. Both α and 
Rs were improved by a basic mobile phase modifier. No improvement was 
observed between acid modified mobile phase and non-modified mobile phase. 
6.3.6 Cytotoxicity 
    The cytotoxicities of the three components were studied in PC3 prostate 
cancer cells. The IC50s of compound #1, #2 and #3 were 10 µM, 10 µM and 3 
µM, respectively. The dimer form showed highest activity among the three 
degradants. 
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Table 1: Calculation of selectivity and resolution parameters of the two major peaks. 
Mobile Phase 
Flow Rate 
(mL/min) 
Organic Solvent 
(%) 
α Rs 
ddH2O/MeOH 
0.8 85 1.027 0.428 
0.8 75 1.028 0.645 
0.6 85 1.034 0.651 
ddH2O/MeOH 
w/ 0.1% Formic 
Acid 
0.5 85 1.038 0.647 
0.5 75 1.034 0.799 
ddH2O/MeOH  
w/ 0.1% TEA 
0.6 90 1.079 1.231 
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6.4 Discussion 
HPLC is an important analytic tool for drug monitoring and quality assurance. It is 
especially important in the field of pharmaceuticals and medical industries because it 
allows both qualitative and quantitative analysis (8). The U.S. Food and Drug 
Administration has established stringent regulations for HPLC tests in these 
industries. In addition, the application of HPLC method enables complex mixtures, 
such as herbal medicine plant extracts, to be separated into individual compounds 
(9).  
The retention of the compound in HPLC can be controlled by the mobile phase 
gradient settings, flow rate and column temperature. Using a gradient with a slow 
increase in the non-polar mobile phase percentage gave a better separation of the 
molecules with similar polarity (Fig.1B). However, this led to a loss of signal intensity 
as the peak itself was wider. In contrast, a steep gradient improved signal intensity 
with a resulting loss of resolution (Fig. 1A). The mobile phase flow rate impacts 
HPLC system pressure, chromatographic quality and analysis time. An appropriate 
flow rate must be chosen for the HPLC system and the column.  At a faster flow rate, 
the analyte may have insufficient time to interact with the stationary phase. In 
comparison, at a lower flow rate, it takes a longer time for the peak to appear at the 
detector (Fig. 1C). Column temperature is another factor that could affect the system 
pressure. Temperature also can increase the column efficiency. With elevated 
temperature, the eluent viscosity was decreased resulting in lower back pressure 
and also improved the diffusion coefficient giving narrower peaks (Fig. 2). The 
shorter retention time generated taller peaks and lowered the detection limits. 
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The most commonly used organic solvents as mobile phases in reverse phase 
chromatography are ACN and MeOH. LC grade ACN has lower absorbance, 
especially for shorter wavelengths (< 250 nm). LC grade ACN as the mobile phase 
results in less ghost peaking for gradient baselines and is best used for high 
sensitivity analysis at short UV wavelengths. With the same mix ratio of water, ACN 
generally has higher elution strength and less back pressure compared to MeOH. In 
addition, the separation selectivity is different between ACN and MeOH. This can be 
explained by that the chemical properties of the organic solvent molecules. MeOH is 
a protic solvent and can undergo polar-polar or ionic interactions with the solutes. 
ACN is an aprotic solvent and forms a binary mixture with water. The reported 
structure of alternol is a polyphenol molecule, and it has enhanced resonance for 
stabilization. The predicted pKas of the molecule are 8.3 and 10.5. At neutral pH, the 
molecules are pronated and positively charged. Therefore, the mixture should have 
a better separation with MeOH than ACN, which was observed.   
HPLC separation is based on mechanisms of adsorption and partitioning, which 
depends on the type of stationary phase used. The stationary phase of the reverse 
phase column used was silica particles functionalized with straight chain alkyl 
groups, such as C18 and C5, or with an aromatic group, phenyl, or a cyano group. A 
C18 column was the most hydrophobic column used in this study. The C18 
stationary phase provides weak H-bonding, no dipole-dipole interaction, no π- π 
interaction, no shape selectivity and moderate ionic interaction. Similar to the C18 
column, the C5 column offers weak H-bonding, no dipole-dipole interaction, no π- π 
interaction and no shape selectivity. The C5 column also provides a strong 
hydrophobic interaction between the stationary phase and the solute, but it is less 
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hydrophobic than C18. In addition, the hydrophobic properties, the C18 reagents are 
bulky and can leave some silanols unreacted (ca. 50%). The C5 reagents are 
smaller than C18 and they have better silanol coverage. Therefore, at pH > 4, 
silanols on C18 column can ionize and add cation-exchange character to the 
column. We showed that with decreased hydrophobicity of the stationary phase, the 
retention of the mixture was reduced (Fig. 4A). In this case, the selectivity of a C5 
column was also compromised. 
Phenyl bonded stationary phase is less hydrophobic than straight chain alkyl 
columns. Phenyl is a Lewis base or an electron donation group. Due to the rigid 
nature of the aromatic ring, solute shape can dictate strong planar shape selectivity. 
It is a weak H-bonding acceptor with weak dipole-dipole attractions, strong donor of 
π- π interaction and weak ionic interaction. Since alternol has a multiple ring 
structure, a phenyl column was used to examine if the mixture could achieve better 
separation. We demonstrated that the mixture had retention on phenyl column; 
however, the selectivity of compounds was very low (Fig. 4B). This indicated that 
using π- π interaction and shape selectivity of the phenol group did not increase 
separation of the compounds mixture. 
A cyano group has a large dipole moment that can interact with other dipole 
molecules in solution. Cyano groups have moderate hydrophobic character from 
alkyl ligands and provide a weak H-bonding acceptor, weak π- π interaction, no 
shape selectivity and strong ionic interaction. The degraded alternol did not have 
enough retention on cyano column, and furthermore, no separation of the mixture 
was observed. This illustrated that the dipole-dipole interaction between the 
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stationary phase and the solute was very weak and was not suitable for this 
compound purification. 
In the reversed phase chromatography, the most polar molecule will be eluted 
first. This is due to polar compound’s minimum interaction with the non-polar 
stationary phase. While increasing the polarity of the mobile phase, retention of 
highly retained molecules will increase. The retention time and selectivity of the 
solutes in HPLC also can be affected by pH and the type of organic modifiers. The 
pH of the mobile phase affects analyte ionization and solvation; therefore, 
interactions of the analytes with the stationary phase will be changed. The retention 
time of ionizable compounds at a certain pH is dependent on their ionization state. 
The hydrophobicity will be decreased with ionization and lead to a shorter HPLC 
retention times.  
In HPLC method development, the most common pH adjustment method is to add 
acid modifiers because the stable pH range of most columns is from 2 to 8. We 
found that with 0.1 % TFA added in the mobile phase the peaks achieved better 
separation, but they still were not fully separated. This indicated that at acidic pH the 
polarities of the mixture compounds were not changed significantly and they may 
have similar chemical structures.   
A basic modifier, 0.1 % TEA, was also added to the mobile phase. The pH 
stability of the column used in this study was from 2 to 12. We showed that the three 
compounds were fully separated at basic conditions. The pKa of TEA is 10.65, and 
the pH of 0.1 % TEA in the mobile phase was about 9.5. The improved separation is 
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probably because the mobile phase pH was between the 2 pKas of the molecule. 
The degrees of ionization were significantly different among the three compounds. 
Selectivity is the retention time ratio of two adjacent peaks. It is an important 
parameter to determine how the compounds are separated. In general, if α equal to 
1, separation efficiency will not improve with further column efficient. Based on the 
fundamental resolution equation, selectivity has a linear relationship with relative 
resolution. We showed that under similar conditions the selectivity was improved 
from 1.034 to 1.079, indicating a 2.32-fold improvement in relative resolution. 
Unlike the selectivity, which is independent of the column efficiency, resolution 
evaluates compound separation based on the complete chromatographic system. In 
general, Rs equal to or more than 1 indicates complete separation. If Rs is less than 
1, the compounds overlapped. By using basic a modifier, the resolution improved 
from 0.651 to 1.231, which is 1.89-fold.  
The molecular weights of each peak were obtained by mass spectrometry in 
negative mode. The masses of the three peaks were 332.0799, 350.0922 and 
700.1927, respectively. The third peak was a dimer of the second. The molecular 
weight of the second peak was 2 mass units off from the reported structure.  After 
re-injection of each peak into the HPLC, we found that the first peak was the 
degradation product from the third peak and, the third peak was degraded from the 
second peak. The second peak was very close to the parent drug and there was no 
claimed compound found. Based on mass spec, the proposed structures of 
degradation compound #1, #2 and #3 are shown in Fig. 1. The proposed alternol 
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degradation mechanisms and formation mechanisms of compound #1, #2 and #3 
are shown in Fig. 7. 
Alternol can be easily oxidized when exposed to air (Fig. 7A). The degradation 
started from the loss of hydrogen atom of the hydroxyl group to form a radical 
intermediate. Then one of its α-Hs was captured by the formed radical spice 
resulting in the oxidized compound (compound #2) which was found at m/z 350 by 
ESI. 
Compound #2, as soon as it was formed, was deprotonated by TEA. The formed 
anion then attacked the one of the carbon atom of the cyclopropane as a nucleophile 
producing the dimer (compound #3) which was found at m/z 700. 
Compound #3 is not stable in the presence of TEA at the temperature of 40 oC.  
The two 8-hydroxy-3,4-dihydronaphthalen-1(2H)-one parts in the molecule were  
oxidized by air  to form two naphthalene-1,8-diol partners in the intermediate, which 
was then hydrolyzed resulting in two molecules of compound #1 which appeared 
m/z 332 by ESI. 
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Fig. 7: Proposed alternol degradation mechanisms. (A) The formation of compound #2 
(MW: 350); (B) The formation of compound #3 (MW: 700); (C) The formation of 
compound #1 (MW: 332). 
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6.5 Conclusions 
Baseline separation of degraded alternol was achieved by a 0.1 % TEA modified 
mobile phases using a C18 column. At neutral and acidic conditions, the three 
mixtures were not fully separated. This indicated that pH adjustment played a key 
role in the alternol degraded compound mixture purification. 
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